Personensuche
Personensuche
Es wurde 1 Person gefunden.
Institut für Dermatologie der Medizinischen Fakultät am Universitätsklinikum Essen
Anschrift
Hufelandstraße 55
45122 Essen
45122 Essen
Telefon
Funktionen
- Direktor/in, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
2021 SS
- Berufsdermatologisches Praktikum (WA)
- Pathophysiologie u. Praxis der Wundheilung (WA)
- Dermatologie und Venerologie (3. Sem. zweiter Abschnitt) (WA)
- Dermatologische Untersuchungsmethoden (PV) (1. Sem. zweiter Abschnitt)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Aktuelle Forschungsthemen
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
Vergangene Veranstaltungen (max. 10)
-
2020 WS
- Dermatologische Untersuchungsmethoden (PV) (1. Sem. zweiter Abschnitt)
- Integriertes Seminar klinische Untersuchungen (1. Abschnitt der Ärztlichen Ausbildung) (nur Wintersemester) (PV)
- Dermatologie und Venerologie (3. Sem. zweiter Abschnitt) (WA)
- Pathophysiologie u. Praxis der Wundheilung (WA)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Berufsdermatologisches Praktikum (WA)
- Aktuelle Forschungsthemen
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
- 2020 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Allosteric and ATP-competitive MEK-inhibition in a novel spitzoid melanoma model with a raf-and phosphorylation-independent mutationIn: Cancers Jg. 13 (2021) Nr. 4, S. 1 - 12
ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access) -
Anticancer innovative therapy congress : Highlights from the 10th anniversary editionIn: Cytokine & Growth Factor Reviews (2021) in press
ISSN: 1879-0305; 1359-6101Online Volltext: dx.doi.org/ -
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 1, S. e001931
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classificationIn: European Journal of Cancer Jg. 149 (2021) S. 94 - 101
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanomaIn: Cancers Jg. 13 (2021) Nr. 4, S. 731
ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt (2021) in press
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ (Open Access) -
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer Jg. 148 (2021) S. 395 - 404
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Melanoma recurrence patterns and management after adjuvant targeted therapy : A multicentre analysisIn: British Journal of Cancer: Multidisciplinary journal of cancer research; BJC Jg. 124 (2021) Nr. 3, S. 574 - 580
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ -
Mental health burden of german cancer patients before and after the outbreak of covid-19 : Predictors of mental health impairmentIn: International Journal of Environmental Research and Public Health = IJERPH Jg. 18 (2021) Nr. 5, S. 1 - 12
ISSN: 1660-4601; 1661-7827Online Volltext: dx.doi.org/ (Open Access) -
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53In: Oncogene Jg. 40 (2021) Nr. 5, S. 980 - 996
ISSN: 1476-5594; 0950-9232Online Volltext: dx.doi.org/ (Open Access) -
Merkel-Zell-KarzinomIn: Der Onkologe (2021) in press
ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/ -
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer Jg. 148 (2021) S. 340 - 347
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionIn: Nature Genetics Jg. 53 (2021) Nr. 3, S. 332 - 341
ISSN: 1061-4036; 1546-1718Online Volltext: dx.doi.org/ -
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer Jg. 148 (2021) S. 61 - 75
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Robustness of convolutional neural networks in recognition of pigmented skin lesionsIn: European Journal of Cancer (EJC) Jg. 145 (2021) S. 81 - 91
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions : Findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. e001621
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology (JEADV) Jg. 35 (2021) Nr. 2, S. 387 - 395
ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV⁶⁰⁰-mutant, stage III melanoma (COMBI-AD) : Exploratory biomarker analyses from a randomised, phase 3 trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 3, S. 358 - 372
ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : a randomised, double-blind, placebo-controlled, phase 2 trialIn: The Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568
ISSN: 1474-547X; 0140-6736Online Volltext: dx.doi.org/ -
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary : Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialIn: European Journal of Cancer Jg. 133 (2020) S. 94 - 103
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionIn: Frontiers in Immunology Jg. 11 (2020) S. 1849
ISSN: 1664-3224Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Artificial Intelligence in Skin Cancer Diagnostics : The Patients' PerspectiveIn: Frontiers in Medicine Jg. 7 (2020) S. 233
ISSN: 2296-858XOnline Volltext: dx.doi.org/ (Open Access) -
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical TrialIn: JAMA Oncology Jg. 6 (2020) Nr. 4, S. 519 - 527
ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ (Open Access) -
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical TrialsIn: JAMA Oncology Jg. 6 (2020) Nr. 8, S. 1256 - 1264
ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ -
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147
ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ (Open Access) -
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 6232
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Jg. 580 (2020) Nr. 7801, S. E1
ISSN: 1476-4687; 0028-0836Online Volltext: dx.doi.org/ -
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesIn: Cancer Immunology, Immunotherapy (2020) in press
ISSN: 1432-0851; 0340-7004Online Volltext: dx.doi.org/ (Open Access) -
COVID-19-Related Fear and Health-Related Safety Behavior in Oncological PatientsIn: Frontiers in Psychology Jg. 11 (2020) S. 1984
ISSN: 1664-1078Online Volltext: dx.doi.org/ (Open Access) -
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 1335
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 2, S. 294 - 305
ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1In: Cell Death and Disease Jg. 11 (2020) Nr. 7,
ISSN: 2041-4889Online Volltext: dx.doi.org/ (Open Access) -
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyIn: PLoS Pathogens Jg. 16 (2020) Nr. 3, S. e1008340
ISSN: 1553-7374; 1553-7366Online Volltext: dx.doi.org/ (Open Access) -
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-iIn: Nature Medicine Jg. 26 (2020) Nr. 10, S. 1557 - 1563
ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ -
Dedifferentiated melanomas : Morpho-phenotypic profile, genetic reprogramming and clinical implicationsIn: Cancer Treatment Reviews Jg. 88 (2020) S. 102060
ISSN: 1532-1967; 0305-7372Online Volltext: dx.doi.org/ -
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer Jg. 131 (2020) S. 18 - 26
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609
ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access) -
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine Jg. 9 (2020) Nr. 7, S. 2060
ISSN: 2077-0383Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitopeIn: European Journal of Immunology: EJI Jg. 50 (2020) Nr. 2, S. 270 - 283
ISSN: 1521-4141; 0014-2980Online Volltext: dx.doi.org/ (Open Access) -
Effect of a Face-Aging Mobile App-Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil : A Cluster-Randomized Clinical TrialIn: JAMA Dermatology Jg. 156 (2020) Nr. 7, S. 737 - 745
ISSN: 2168-6084; 2168-6068Online Volltext: dx.doi.org/ (Open Access) -
Effects of Label Noise on Deep Learning-Based Skin Cancer ClassificationIn: Frontiers in Medicine Jg. 7 (2020) S. 177
ISSN: 2296-858XOnline Volltext: dx.doi.org/ (Open Access) -
Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses : A prospective, randomized and rater-blinded study (ACTICAP)In: Journal of the European Academy of Dermatology and Venereology Jg. 34 (2020) Nr. 12, S. E844 - E846
ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/ -
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 144 - 152
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“)In: Der Hautarzt Jg. 71 (2020) Nr. 11, S. 887 - 897
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ (Open Access) -
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ (Open Access) -
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaIn: New England Journal of Medicine Jg. 383 (2020) Nr. 12, S. 1139 - 1148
ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 33, S. 3937 - 3946
ISSN: 1527-7755; 0732-183XOnline Volltext: dx.doi.org/ (Open Access) -
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology Jg. 183 (2020) Nr. 5, S. 928 - 939
ISSN: 1365-2133; 0007-0963; 0366-2845Online Volltext: dx.doi.org/ (Open Access) -
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityIn: Nature Genetics Jg. 52 (2020) Nr. 5, S. 494 - 504
ISSN: 1546-1718; 1061-4036Online Volltext: dx.doi.org/ -
Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma : DATA from Columbus, a Phase 3 Trial in BRAF-Mutant MelanomaIn: Value in Health Jg. 23 (2020) Nr. Suppl. 2, S. 428
ISSN: 1098-3015; 1524-4733Online Volltext: dx.doi.org/ -
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e000897
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Immuntherapie beim malignen MelanomIn: Der Internist: Organ des Berufsverbandes Deutscher Internisten Jg. 61 (2020) Nr. 7, S. 669 - 675
ISSN: 1432-1289; 0020-9554Online Volltext: dx.doi.org/ (Open Access) -
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000395
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Inhibition of haspin kinase promotes cell-intrinsic and extrinsic antitumor activityIn: Cancer Research Jg. 80 (2020) Nr. 4, S. 798 - 810
ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics Jg. 52 (2020) Nr. 12, S. 1373 - 1383
ISSN: 1546-1718; 1061-4036Online Volltext: dx.doi.org/ -
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy : Analysis from phase 2 and 3 clinical trialsIn: European Journal of Cancer Jg. 125 (2020) S. 114 - 120
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Macrophages/microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brainIn: Frontiers in Immunology Jg. 11 (2020) Article-No: 120
ISSN: 1664-3224Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Malignes MelanomIn: Der Pathologe Jg. 41 (2020) Nr. 3, S. 281 - 292
ISSN: 0172-8113Online Volltext: dx.doi.org/ -
Malignes MelanomIn: Der Onkologe: Organ der Deutschen Krebsgesellschaft e.V. Jg. 26 (2020) Nr. 1, S. 75 - 87
ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/ -
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720
ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/ -
Malignes MelanomIn: Der Hautarzt Jg. 71 (2020) S. 63 - 77
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ -
Melanoma brain metastases – Interdisciplinary management recommendations 2020In: Cancer Treatment Reviews Jg. 89 (2020) S. 102083
ISSN: 1532-1967; 0305-7372Online Volltext: dx.doi.org/ -
Metabolic heterogeneity confers differences in melanoma metastatic potentialIn: Nature Jg. 577 (2020) Nr. 7788, S. 115 - 120
ISSN: 1476-4687; 0028-0836Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Onkokardiologie : Neue Herausforderungen, neue MöglichkeitenIn: Herz: cardiovascular diseases Jg. 45 (2020) S. 619 - 625
ISSN: 1615-6692; 0340-9937Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1,
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Pan-cancer analysis of whole genomesIn: Nature Jg. 578 (2020) Nr. 7793, S. 82 - 93
ISSN: 0028-0836; 1476-4687Online Volltext: dx.doi.org/ (Open Access) -
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology (2020) in press
ISSN: 1432-1335; 0171-5216Online Volltext: dx.doi.org/ (Open Access) -
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma : Primary analysis of fixed-dosing, long-term outcome of weight-based dosingIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000775
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIn: Clinical Cancer Research Jg. 26 (2020) Nr. 9, S. 2257 - 2267
ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/ -
Prognosis of patients with stage III melanoma according to American joint committee on cancer version 8 : A reassessment on the basis of 3 independent stage III melanoma cohortsIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 22, S. 2543 - 2551
ISSN: 1527-7755; 0732-183XOnline Volltext: dx.doi.org/ (Open Access) -
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 153 - 159
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas : Patient‐reported outcomes from the MIKIE studyIn: Journal of the European Academy of Dermatology and Venereology: JEADV Jg. 34 (2020) Nr. 9, S. e526 - e529
ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/ -
Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A ReviewIn: JAMA Oncology (2020) in press
ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ -
Reply to the letter to the editor: ‘Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images’In: European Journal of Cancer Jg. 130 (2020) S. 262 - 264
ISSN: 1879-0852; 1879-2995; 0959-8049; 0014-2964Online Volltext: dx.doi.org/ (Open Access) -
Retraction Note to : cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cellsIn: Cellular and Molecular Life Sciences Jg. 77 (2020) Nr. 5, S. 963
ISSN: 1420-9071; 1420-682XOnline Volltext: dx.doi.org/ -
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 4748
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia : A prospective studyIn: World Journal of Surgical Oncology Jg. 18 (2020) Nr. 1, S. 53
ISSN: 1477-7819Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapyIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e001689
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Sex differences in oncogenic mutational processesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 4330
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma : A joint expert opinionIn: Journal of the European Academy of Dermatology and Venereology Jg. 34 (2020) Nr. 9, S. 1944 - 1956
ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer Jg. 130 (2020) S. 126 - 138
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell CarcinomaIn: The Journal of Investigative Dermatology Jg. 140 (2020) Nr. 11, S. 2146 - 2156.e4
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ -
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyIn: The Journal of Clinical Investigation Jg. 130 (2020) Nr. 8, S. 4266 - 4281
ISSN: 1558-8238; 0021-9738Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Jg. 577 (2020) Nr. 7791, S. 561 - 565
ISSN: 0028-0836; 1476-4687Online Volltext: dx.doi.org/ -
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitionsIn: European Journal of Cancer Jg. 138 (2020) S. 68 - 76
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Update on tolerability and overall survival in COLUMBUS : landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanomaIn: European Journal of Cancer Jg. 126 (2020) S. 33 - 44
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: Journal of Dermatology Jg. 47 (2020) Nr. 6, S. 629 - 635
ISSN: 1346-8138; 0385-2407Online Volltext: dx.doi.org/ -
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer Jg. 111 (2019) S. 148 - 154
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Adverse events 2.0—Let us get SERIOs : New reporting for adverse event outcomes needed in the era of immunooncologyIn: European Journal of Cancer Jg. 112 (2019) S. 29 - 31
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study : incidence, course and managementIn: European Journal of Cancer Jg. 119 (2019) S. 97 - 106
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1)In: The Journal of Investigative Dermatology Jg. 139 (2019) Nr. 10, S. 2235 - 2238.e5
ISSN: 0022-202XOnline Volltext: dx.doi.org/ (Open Access) -
Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections - A cross-sectional, single-center studyIn: Sexually Transmitted Infections Jg. 95 (2019) Nr. 2, S. 95 - 98
ISSN: 1472-3263; 1368-4973Online Volltext: dx.doi.org/ -
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanomaIn: JCO Precision Oncology Jg. 3 (2019)
ISSN: 2473-4284Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in MelanomaIn: JAMA Network Open Jg. 2 (2019) Nr. 8, S. e199020
ISSN: 2574-3805Online Volltext: dx.doi.org/ (Open Access) -
B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV : Results from the HIV-HEART studyIn: International Journal of Cardiology Jg. 281 (2019) S. 127 - 132
ISSN: 1874-1754; 0167-5273Online Volltext: dx.doi.org/ -
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanomaIn: OncoTarget Jg. 10 (2019) Nr. 19, S. 1850 - 1859
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Cardiovascular Adverse Events Associated with BRAF and MEK Inhibitors : A Systematic Review and Meta-analysisIn: JAMA Network Open Jg. 2 (2019) Nr. 8, S. e198890
ISSN: 2574-3805Online Volltext: dx.doi.org/ (Open Access) -
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_suppl, S. 9510
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer Jg. 119 (2019) S. 66 - 76
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Comparing artificial intelligence algorithms to 157 German dermatologists : the melanoma classification benchmarkIn: European Journal of Cancer Jg. 111 (2019) S. 30 - 37
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Complex formation with monomeric α-tubulin and importin 13 fosters c-jun protein stability and is required for c-jun’s nuclear translocation and activityIn: Cancers Jg. 11 (2019) Nr. 11, S. 1806
ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access) -
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : final update of the pivotal ERIVANCE BCC studyIn: BMC Cancer Jg. 19 (2019) S. 366
ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access) -
Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence : A call for prospective data’ (European Journal of Cancer (2019) 119 (30–34), (S0959804919304095), (10.1016/j.ejca.2019.07.009))In: European Journal of Cancer Jg. 123 (2019) S. 171
ISSN: 0959-8049; 1879-0852; 1879-2995Online Volltext: dx.doi.org/ (Open Access) -
Deep learning outperformed 11 pathologists in the classification of histopathological melanoma imagesIn: European Journal of Cancer Jg. 118 (2019) S. 91 - 96
ISSN: 0959-8049; 0277-5379; 0964-1947; 1879-0852Online Volltext: dx.doi.org/ (Open Access) -
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer Jg. 113 (2019) S. 47 - 54
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Deep neural networks are superior to dermatologists in melanoma image classificationIn: European Journal of Cancer Jg. 119 (2019) S. 11 - 17
ISSN: 0959-8049; 1879-0852; 0964-1947; 0277-5379Online Volltext: dx.doi.org/ (Open Access) -
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_Suppl, S. 2515 - 2515
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaIn: European Journal of Cancer Jg. 116 (2019) S. 207 - 215
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 TrialIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 11, S. 867 - 875
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access) -
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 5, S. 765 - 772
ISSN: 1432-0851; 0340-7004Online Volltext: dx.doi.org/ -
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaIn: The New England Journal of Medicine Jg. 381 (2019) Nr. 16, S. 1535 - 1546
ISSN: 1533-4406Online Volltext: dx.doi.org/ -
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanomaIn: European Journal of Cancer Jg. 109 (2019) S. 61 - 69
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Five-year outcomes with dabrafenib plus trametinib in metastatic melanomaIn: The New England Journal of Medicine Jg. 381 (2019) Nr. 7, S. 626 - 636
ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ -
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral NaeviIn: Cancers Jg. 11 (2019) Nr. 4, S. 546
ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapyIn: Cancer Research Jg. 79 (2019) Nr. 11, S. 2947 - 2961
ISSN: 0008-5472; 0099-7013; 0099-7374; 1538-7445Online Volltext: dx.doi.org/ -
Health-related quality of life in patients with fully resected BRAFV⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: European Journal of Cancer Jg. 123 (2019) S. 155 - 161
ISSN: 0959-8049; 0014-2964Online Volltext: dx.doi.org/ (Open Access) -
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7
ISSN: 1610-0379; 1610-0387 -
Immunotherapy in non-melanoma skin cancer : Updates and new perspectivesIn: Drugs in Context Jg. 8 (2019) S. 212583
ISSN: 1740-4398; 1745-1981Online Volltext: dx.doi.org/ (Open Access) -
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer Jg. 119 (2019) S. 18 - 29
ISSN: 0959-8049; 1879-0852; 1879-2995; 0964-1947; 0277-5379Online Volltext: dx.doi.org/ -
Informations- und Hilfsangebote für Melanompatienten : Präferenzielle Unterschiede zwischen Patienten und ÄrztenIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 17 (2019) Nr. 6, S. 652 - 654
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927
ISSN: 1078-8956; 1546-170XOnline Volltext: dx.doi.org/ (Open Access) -
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition : a case seriesIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 6, S. 983 - 990
ISSN: 0340-7004; 1432-0851Online Volltext: dx.doi.org/ -
MerkelzellkarzinomIn: Best Practice Onkologie Jg. 14 (2019) Nr. 7/8, S. 312 - 323
ISSN: 0946-4565; 1862-8559Online Volltext: dx.doi.org/ -
MerkelzellkarzinomIn: Der Hautarzt Jg. 70 (2019) Nr. 3, S. 215 - 227
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ -
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141
ISSN: 2051-1426Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophilsIn: International Journal of Cancer Jg. 144 (2019) Nr. 1, S. 136 - 149
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ -
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology Jg. 30 (2019) Nr. 2, S. 317 - 324
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access) -
Pathologist-level classification of histopathological melanoma images with deep neural networksIn: European Journal of Cancer Jg. 115 (2019) S. 79 - 83
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 20 (2019) Nr. 5, S. 701 - 710
ISSN: 1474-5488Online Volltext: dx.doi.org/ -
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence : A call for prospective dataIn: European Journal of Cancer Jg. 119 (2019) S. 30 - 34
ISSN: 0964-1947; 0959-8049; 0277-5379; 1879-0852Online Volltext: dx.doi.org/ (Open Access) -
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaIn: European Journal of Cancer Jg. 116 (2019) S. 148 - 157
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery Jg. 56 (2019) Nr. 6, S. 1104 - 1109
ISSN: 1873-734X; 1010-7940; 1567-4258Online Volltext: dx.doi.org/ -
Publisher Correction : Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 10 (2019) Nr. 1, S. 299
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 10 (2019) Nr. 1, S. 299
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_Suppl, S. 9568
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Quality, Readability, and Understandability of German Booklets Addressing Melanoma PatientsIn: Journal of Cancer Education Jg. 34 (2019) Nr. 4, S. 760 - 767
ISSN: 1543-0154; 0885-8195Online Volltext: dx.doi.org/ -
Reply to E. Hindié and K.R. HessIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 1356 - 1358
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment : A single-arm, open-label, phase II study (CheckMate 172)In: European Journal of Cancer Jg. 121 (2019) S. 144 - 153
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment : a single-arm, open-label, phase II study (CheckMate 172)In: European Journal of Cancer Jg. 119 (2019) S. 168 - 178
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Salvage therapy after failure from anti-PD-1 single agent treatment : A Study by the German ADOReg melanoma registryIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15_Suppl, S. 9505
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma : Study protocol for a multicentric randomized controlled trialIn: Trials Jg. 20 (2019) Nr. 1, S. 99
ISSN: 1745-6215Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer Jg. 109 (2019) S. 137 - 153
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Sources of information and support for melanoma patients : differences between patients' and clinicians' preferences, Clinical letterIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 17 (2019) Nr. 6, S. 652 - 654
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Superior skin cancer classification by the combination of human and artificial intelligenceIn: European Journal of Cancer Jg. 120 (2019) S. 114 - 121
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy : Three-Year Follow-up of a Randomized Phase 3 TrialIn: JAMA Oncology Jg. 5 (2019) Nr. 2, S. 187 - 194
ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ -
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeIn: Cell Research Jg. 29 (2019) Nr. 10, S. 846 - 861
ISSN: 1748-7838; 1001-0602Online Volltext: dx.doi.org/ (Open Access) -
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksIn: European Journal of Cancer Jg. 119 (2019) S. 57 - 65
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsIn: The Journal of Investigative Dermatology Jg. 139 (2019) Nr. 12, S. 2506 - 2516.e10
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ -
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaIn: Cell Reports Jg. 27 (2019) Nr. 12, S. 3573 - 3586.e7
ISSN: 2211-1247Online Volltext: dx.doi.org/ (Open Access) -
The prognostic value of sentinel lymph nodes on distant metastasis–free survival in patients with high-risk squamous cell carcinomaIn: European Journal of Cancer Jg. 111 (2019) S. 107 - 115
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ -
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 501 - 503
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodiesIn: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 343
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Unmet information needs of patients with melanoma in GermanyIn: Melanoma Research Jg. 29 (2019) Nr. 2, S. 196 - 204
ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/ -
ctDNA as a noninvasive monitoring tool in metastatic melanomaIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. Suppl. 15, S. 9548
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell Jg. 175 (2018) Nr. 4, S. 984 - 997.e24
ISSN: 1097-4172; 0092-8674Online Volltext: dx.doi.org/ (Open Access) -
A Face-Aging App for Smoking Cessation in a Waiting Room Setting : Pilot Study in an HIV Outpatient ClinicIn: Journal of Medical Internet Research Jg. 20 (2018) Nr. 8, S. e10976
ISSN: 1439-4456; 1438-8871Online Volltext: dx.doi.org/ (Open Access) -
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanomaIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 36 (2018) Nr. 1, S. 103 - 113
ISSN: 1573-0646; 0167-6997Online Volltext: dx.doi.org/ -
A skin cancer prevention facial-aging mobile app for secondary schools in Brazil : Appearance-focused interventional studyIn: JMIR mhealth and uhealth Jg. 6 (2018) Nr. 3, S. e60
ISSN: 2291-5222Online Volltext: dx.doi.org/ (Open Access) -
A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students : protocol for a randomised controlled trialIn: BMJ Open Jg. 8 (2018) Nr. 3, S. e018299
ISSN: 2053-3624; 2044-6055Online Volltext: dx.doi.org/ (Open Access) -
Actinic keratoses treated with cold atmospheric plasmaIn: Journal of the European Academy of Dermatology and Venereology Jg. 32 (2018) Nr. 1, S. e37 - e39
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Adjuvant melanoma therapy with new drugs : should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?In: The Lancet Oncology Jg. 19 (2018) Nr. 12, S. e720 - e725
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Adjuvant pembrolizumab versus placebo in resected stage III melanomaIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 19, S. 1789 - 1801
ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 4, S. 510 - 520
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Advanced cutaneous squamous cell carcinoma : A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGIn: European Journal of Cancer Jg. 96 (2018) S. 34 - 43
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialIn: Annals of Oncology: official journal of the European Society for Medical Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii446
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Adverse events of special interest in the phase 3 COLUMBUS studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9567 - 9567
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-Cell populationsIn: Clinical Cancer Research Jg. 24 (2018) Nr. 21, S. 5347 - 5356
ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/ -
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysisIn: The Lancet Oncology Jg. 19 (2018) Nr. 3, S. 310 - 322
ISSN: 1470-2045Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profilesIn: Modern Pathology Jg. 31 (2018) Nr. 3, S. 418 - 428
ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 12, S. 2093 - 2102
ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ -
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell Jg. 173 (2018) Nr. 3, S. 624 - 633.e8
ISSN: 1097-4172; 0092-8674Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity : A meta-analysis of approximately 29,000 cancer patientsIn: European Journal of Preventive Cardiology Jg. 25 (2018) Nr. 5, S. 482 - 494
ISSN: 2047-4881; 2047-4873Online Volltext: dx.doi.org/ -
Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinomaIn: Clinical Cancer Research Jg. 24 (2018) Nr. 23, S. 5873 - 5882
ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/ -
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsIn: The British Journal of Cancer: BJC Jg. 118 (2018) Nr. 6, S. 785 - 792
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access) -
Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma : A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]In: European Journal of Cancer Jg. 93 (2018) S. 158
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer Jg. 95 (2018) S. 104 - 108
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9590 - 9590
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Eighth American Joint Committee on Cancer (AJCC) melanoma classification : Let us reconsider stage IIIIn: European Journal of Cancer Jg. 91 (2018) S. 168 - 170
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) : a multicentre, open-label, randomised phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 5, S. 603 - 615
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access) -
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialIn: Annals of Oncology: official journal of the European Society for Medical Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii445
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology Jg. 7 (2018) Nr. 8, S. e1450127
ISSN: 2162-402X; 2162-4011Online Volltext: dx.doi.org/ -
F-18-FDG PET/MR including DWI in initial N-Staging in patients with malignant melanoma : Is it a possible replacement for sentinel lymph node biopsy?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 38
ISSN: 1619-7070; 1619-7089 -
Facial-aging app availability in waiting rooms as a potential opportunity for skin cancer preventionIn: JAMA Dermatology Jg. 154 (2018) Nr. 9, S. 1085 - 1086
ISSN: 2168-6068; 2168-6084Online Volltext: dx.doi.org/ -
Fear of cancer progression in patients with stage IA malignant melanomaIn: European Journal of Cancer Care Jg. 27 (2018) Nr. 5, S. e12901
ISSN: 1365-2354; 0961-5423Online Volltext: dx.doi.org/ -
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics Jg. 50 (2018) Nr. 9, S. 1271 - 1281
ISSN: 1061-4036; 1546-1718Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Information-seeking and use of information resources among melanoma patients of German skin cancer centersIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 16 (2018) Nr. 9, S. 1093 - 1101
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Informationsangebote für Melanompatienten und ihre Bekanntheit unter BetroffenenIn: Der Hautarzt Jg. 69 (2018) Nr. 4, S. 335 - 339
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ -
Integrated genomic classification of melanocytic tumors of the central nervous system using mutation analysis, copy number alterations, and DNA methylation profilingIn: Clinical Cancer Research Jg. 24 (2018) Nr. 18, S. 4494 - 4504
ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/ -
Intraoperative use of LIGHTVISION : a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patientsIn: European Journal of Dermatology, EJD Jg. 28 (2018) Nr. 4, S. 532 - 534
ISSN: 1952-4013; 1167-1122Online Volltext: dx.doi.org/ -
Intraventricular melanocytoma diagnosis confirmed by gene mutation profileIn: Neuropathology Jg. 38 (2018) Nr. 3, S. 288 - 292
ISSN: 1440-1789; 0919-6544Online Volltext: dx.doi.org/ -
Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapyIn: Clinical Chemistry Jg. 64 (2018) Nr. 5, S. 830 - 842
ISSN: 1530-8561; 0009-9147Online Volltext: dx.doi.org/ -
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III MelanomaIn: Journal of Clinical Oncology Jg. 36 (2018) Nr. 35, S. 3441 - 3449
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access) -
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade : Results of a retrospective multicentre analysis of 364 patientsIn: European Journal of Cancer Jg. 98 (2018) S. 10 - 16
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
MelanomaIn: The Lancet Jg. 392 (2018) Nr. 10151, S. 971 - 984
ISSN: 0140-6736; 1474-547XOnline Volltext: dx.doi.org/ -
MerkelzellkarzinomIn: Der Onkologe Jg. 24 (2018) Nr. 12, S. 1037 - 1049
ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/ -
Mit Nivolumab und Pembrolizumab gegen das Melanom : Wirkprinzip und Umgang mit immunvermittelten Nebenwirkungen der Anti-PD1-TherapieIn: Deutsche Apotheker Zeitung: DAZ Jg. 158 (2018) Nr. 30,
ISSN: 0011-9857 -
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9574 - 9574
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
NF1 mutations in conjunctival melanomaIn: The British Journal of Cancer: BJC Jg. 118 (2018) Nr. 9, S. 1243 - 1247
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access) -
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 11, S. 1480 - 1492
ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ -
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 9 (2018) Nr. 1, S. 4774
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006 : A randomised clinical trialIn: European Journal of Cancer Jg. 101 (2018) S. 236 - 243
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ (Open Access) -
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)In: Annals of Oncology: official journal of the European Society for Medical Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii735
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 10, S. 1315 - 1327
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037 : A Randomized, Controlled, Open-Label Phase III TrialIn: Journal of Clinical Oncology Jg. 36 (2018) Nr. 4, S. 383 - 390
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term TherapyIn: Molecular Imaging and Biology Jg. 20 (2018) Nr. 1, S. 124 - 130
ISSN: 1860-2002; 1536-1632Online Volltext: dx.doi.org/ -
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaIn: The New England Journal of Medicine Jg. 379 (2018) Nr. 4, S. 341 - 351
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.In: Journal of Clinical Oncology Jg. 36 (2018) Nr. 5 Suppl., S. 183
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaIn: European Journal of Cancer Jg. 88 (2018) S. 67 - 76
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancerIn: Proceedings of the National Academy of Sciences of the United States of America Jg. 115 (2018) Nr. 25, S. E5766 - E5775
ISSN: 1091-6490; 0027-8424Online Volltext: dx.doi.org/ -
Patient-reported outcomes with nivolumab in advanced solid cancersIn: Cancer Treatment Reviews Jg. 70 (2018) S. 75 - 87
ISSN: 0305-7372; 1532-1967Online Volltext: dx.doi.org/ (Open Access) -
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer Jg. 99 (2018) S. 58 - 65
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanomaIn: ESMO Open Jg. 3 (2018) Nr. 5, S. e000388
ISSN: 2059-7029Online Volltext: dx.doi.org/ (Open Access) -
Postsurgical treatment of split skin graft donor sites in dermatological departmentsIn: The International Journal of Lower Extremity Wounds Jg. 17 (2018) Nr. 1, S. 22 - 29
ISSN: 1534-7346; 1552-6941Online Volltext: dx.doi.org/ -
Predictors of quality of life in melanoma patients 4 years after diagnosis : Results of a nationwide cohort study in GermanyIn: Journal of Psychosocial Oncology Jg. 36 (2018) Nr. 6, S. 734 - 753
ISSN: 1540-7586; 0734-7332Online Volltext: dx.doi.org/ -
Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912)In: Ophthalmology Jg. 125 (2018) Nr. 11, S. e78 - e79
ISSN: 0161-6420; 1549-4713Online Volltext: dx.doi.org/ -
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studyIn: European Journal of Cancer Jg. 91 (2018) S. 116 - 124
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Reply to M. Horiguchi et al [Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment]In: Journal of Clinical Oncology Jg. 36 (2018) Nr. 7, S. 721
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Role of elevated PHIP copy number as a prognostic and progression marker for cutaneous melanomaIn: Clinical Cancer Research Jg. 24 (2018) Nr. 17, S. 4119 - 4125
ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ -
STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-αIn: Melanoma Research Jg. 28 (2018) Nr. 3, S. 204 - 210
ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/ -
Sebaceous tumours: more than skin deepIn: Gut Jg. 67 (2018) Nr. 11, S. 2045 - 2053
ISSN: 0017-5749; 1468-3288Online Volltext: dx.doi.org/ -
Skin Cancer Classification using Convolutional Neural Networks : Systematic ReviewIn: Journal of Medical Internet Research Jg. 20 (2018) Nr. 10, S. e11936
ISSN: 1439-4456; 1438-8871Online Volltext: dx.doi.org/ (Open Access) -
Teledermatology : Comparison of Store-and-Forward Versus Live Interactive Video ConferencingIn: Journal of Medical Internet Research Jg. 20 (2018) Nr. 10, S. e11871
ISSN: 1438-8871; 1439-4456Online Volltext: dx.doi.org/ (Open Access) -
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskIn: Genes, Chromosomes and Cancer Jg. 57 (2018) Nr. 11, S. 564 - 572
ISSN: 1045-2257; 1098-2264Online Volltext: dx.doi.org/ -
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy : A survey in German melanoma patients and their treating physiciansIn: OncoTarget Jg. 9 (2018) Nr. 40, S. 26217 - 26225
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety Jg. 17 (2018) Nr. 1, S. 73 - 87
ISSN: 1744-764X; 1474-0338Online Volltext: dx.doi.org/ -
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy ResistanceIn: Journal of the National Cancer Institute Jg. 110 (2018) Nr. 6, S. 677 - 681
ISSN: 0198-0157; 0027-8874Online Volltext: dx.doi.org/ -
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology: official journal of the European Society for Medical Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii734 - viii735
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8,
ISSN: 1569-8041; 0923-7534 -
Willingness to pay for a cure of low-risk melanoma patients in GermanyIn: PLoS ONE Jg. 13 (2018) Nr. 5, S. e0197780
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
A Dermatologist's ammunition in the war against smoking : a photoaging appIn: Journal of Medical Internet Research Jg. 19 (2017) Nr. 9, S. e326
ISSN: 1439-4456Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
A medical student-delivered smoking prevention program, education against tobacco, for secondary schools in Germany : Randomized controlled trialIn: Journal of Medical Internet Research Jg. 19 (2017) Nr. 6, S. e199
ISSN: 1439-4456Online Volltext: dx.doi.org/ (Open Access) -
A smoking prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised trial.In: BMJ Open Jg. 7 (2017) S. e018589
ISSN: 2053-3624; 2044-6055Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications Jg. 8 (2017) S. 15440
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic TumorsIn: The Journal of Investigative Dermatology Jg. 137 (2017) Nr. 9, S. 2033 - 2035
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ -
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology Jg. 30 (2017) Nr. 3, S. 350 - 356
ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 377 (2017) Nr. 19, S. 1813 - 1823
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 4, S. 435 - 445
ISSN: 1470-2045Online Volltext: dx.doi.org/ -
CheckpointinhibitorenIn: Der Onkologe Jg. 23 (2017) Nr. 8, S. 619 - 625
ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/ -
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma : a multicenter randomized phase-3 DeCOG trialIn: OncoTarget Jg. 8 (2017) Nr. 44, S. 76029 - 76043
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer Jg. 86 (2017) S. 248 - 256
ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/ -
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma : long-term survival and safety analysis of a phase 3 studyIn: Annals of Oncology Jg. 28 (2017) Nr. 7, S. 1631 - 1639
ISSN: 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma : Final results from the global, single-arm, phase ii team trialIn: Annals of Oncology Jg. 28 (2017) Nr. 6, S. 1380 - 1387
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access) -
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events : a pooled analysis of randomized phase II and III trialsIn: Journal of Clinical Oncology Jg. 35 (2017) Nr. 34, S. 3807 - 3814
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in EuropeIn: OncoTarget Jg. 8 (2017) Nr. 45, S. 79731 - 79741
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaIn: European Journal of Cancer Jg. 86 (2017) S. 37 - 45
ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/ -
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science Jg. 58 (2017) Nr. 9, S. 3464 - 3470
ISSN: 1552-5783; 0146-0404Online Volltext: dx.doi.org/ (Open Access) -
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer Jg. 83 (2017) S. 142 - 145
ISSN: 0959-8049; 1879-2995Online Volltext: dx.doi.org/ -
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma modelIn: OncoTarget Jg. 8 (2017) Nr. 17, S. 28312 - 28327
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Health-related quality of life results from the phase III CheckMate 067 studyIn: European Journal of Cancer Jg. 82 (2017) S. 80 - 91
ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/ (Open Access) -
IRF4 rs12203592 functional variant and melanoma survivalIn: International Journal of Cancer Jg. 140 (2017) Nr. 8, S. 1845 - 1849
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ -
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinomaIn: OncoImmunology Jg. 6 (2017) Nr. 10, S. e1338237
ISSN: 2162-402X; 2162-4011Online Volltext: dx.doi.org/ -
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology Jg. 43 (2017) Nr. 3, S. 604 - 611
ISSN: 1532-2157; 0748-7983Online Volltext: dx.doi.org/ -
Integrative analysis identifies four molecular and clinical subsets in uveal melanomaIn: Cancer Cell Jg. 32 (2017) Nr. 2, S. 204 - 220.e15
ISSN: 1535-6108; 1878-3686Online Volltext: dx.doi.org/ (Open Access) -
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 5, S. 611 - 622
ISSN: 1470-2045Online Volltext: dx.doi.org/ -
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaIn: European Journal of Cancer Jg. 75 (2017) S. 47 - 55
ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/ -
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : final update of the pivotal ERIVANCE BCC studyIn: BMC Cancer Jg. 17 (2017) S. 332
ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access) -
MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapyIn: Cancer Research Jg. 77 (2017) Nr. 17, S. 4697 - 4709
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seqIn: OncoTarget Jg. 8 (2017) Nr. 1, S. 846 - 862
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Melanoma diagnosed in lesions previously treated by laser therapyIn: The Journal of Dermatology Jg. 44 (2017) Nr. 1, S. 23 - 28
ISSN: 1346-8138; 0385-2407Online Volltext: dx.doi.org/ -
Merkel cell carcinoma : Epidemiology, prognosis, therapy and unmet medical needsIn: European Journal of Cancer Jg. 71 (2017) S. 53 - 69
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Metastatic recurrence of 17-year relapse-free melanoma during anti-TNFa therapyIn: Journal of the European Academy of Dermatology and Venereology Jg. 31 (2017) Nr. 8, S. e368 - e369
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression : Analysis of 2 Phase 3 Clinical TrialsIn: JAMA Oncology Jg. 3 (2017) Nr. 11, S. 1511 - 1519
ISSN: 2374-2437; 2374-2445Online Volltext: dx.doi.org/ -
Overall survival with combined nivolumab and ipilimumab in advanced melanomaIn: The New England Journal of Medicine Jg. 377 (2017) Nr. 14, S. 1345 - 1356
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsIn: European Journal of Cancer Jg. 73 (2017) S. 61 - 70
ISSN: 1879-2995; 0959-8049; 0014-2964; 1879-0852Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study.In: JMIR mhealth and uhealth Jg. 5 (2017) Nr. 7, S. e101
ISSN: 2291-5222 -
Photoaging mobile apps in school-based melanoma prevention: pilot studyIn: Journal of Medical Internet Research Jg. 19 (2017) Nr. 9, S. e319
ISSN: 1439-4456Online Volltext: dx.doi.org/ (Open Access) -
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumabIn: Journal of Cancer Research and Clinical Oncology Jg. 143 (2017) Nr. 10, S. 1977 - 1984
ISSN: 0171-5216Online Volltext: dx.doi.org/ -
Predictors of responses to immune checkpoint blockade in advanced melanomaIn: Nature Communications Jg. 8 (2017) S. 592
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Prolongation of the QTc interval in HIV-infected individuals compared to the general populationIn: Infection Jg. 45 (2017) Nr. 5, S. 659 - 667
ISSN: 0300-8126; 1439-0973Online Volltext: dx.doi.org/ -
S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 15 (2017) Nr. 6, S. e1 - e41
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939
ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Safety profile of nivolumab monotherapy : a pooled analysis of patients with advanced melanomaIn: Journal of Clinical Oncology Jg. 35 (2017) Nr. 7, S. 785 - 792
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV-positive men who have sex with men (MSM) – approaches for medical preventionIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 15 (2017) Nr. 4, S. 421 - 428
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Jg. 8 (2017) S. 14447
ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access) -
Survival of patients with advanced metastatic melanoma : the impact of novel therapies–update 2017In: European Journal of Cancer Jg. 83 (2017) S. 247 - 257
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanomaIn: OncoTarget Jg. 8 (2017) Nr. 14, S. 23760 - 23774
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 40683 - 40692
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasisIn: Cancer Research Jg. 77 (2017) Nr. 17, S. 4684 - 4696
ISSN: 0008-5472; 0008-5472Online Volltext: dx.doi.org/ -
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsIn: European Journal of Cancer Jg. 82 (2017) S. 45 - 55
ISSN: 1879-2995; 0959-8049; 0014-2964; 1879-0852Online Volltext: dx.doi.org/ -
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 3, S. 404 - 412
ISSN: 1470-2045Online Volltext: dx.doi.org/ -
Update der S3-Leitlinie zum malignen Melanom : aktuelle Empfehlungen für das fortgeschrittene MelanomIn: Best Practice Onkologie Jg. 12 (2017) Nr. 2, S. 110 - 118
ISSN: 0946-4565; 1862-8559Online Volltext: dx.doi.org/ -
Update on the clinical use of kinase inhibitors in melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 15 (2017) Nr. 9, S. 887 - 893
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Vemurafenib in metastatic melanoma patients with brain metastases : An open-label, single-arm, phase 2, multicentre studyIn: Annals of Oncology Jg. 28 (2017) Nr. 3, S. 634 - 641
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6,
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trialIn: Annals of Oncology Jg. 27 (2016) Nr. 8, S. 1625 - 1632
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1145P
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trialsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1140P
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 22, S. 5487 - 5496
ISSN: 1078-0432Online Volltext: dx.doi.org/ (Open Access) -
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 12, S. 2908 - 2918
ISSN: 1078-0432Online Volltext: dx.doi.org/ (Open Access) -
Checkpoint inhibitors : a new standard of care for advanced Merkel cell carcinoma?In: The Lancet Oncology Jg. 17 (2016) Nr. 10, S. 1337 - 1339
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer Jg. 67 (2016) S. 66 - 72
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeIn: Science Jg. 351 (2016) Nr. 6280, S. 1463 - 1469
ISSN: 0036-8075; 1095-9203Online Volltext: dx.doi.org/ -
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsIn: Clinical Cancer Research Jg. 22 (2016) Nr. 3, S. 567 - 574
ISSN: 1078-0432Online Volltext: dx.doi.org/ (Open Access) -
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyIn: European Journal of Cancer Jg. 60 (2016) S. 190 - 209
ISSN: 1879-0852; 1879-2995Online Volltext: dx.doi.org/ -
Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation SignatureIn: The Journal of Investigative Dermatology Jg. 136 (2016) Nr. 7, S. 1526 - 1528
ISSN: 0022-202X; 1523-1747Online Volltext: dx.doi.org/ -
Eine Übersicht über Therapiefortschritte in den letzten 50 Jahren beim Metastasierten MelanomIn: Drug Research Jg. 66 (2016) Nr. S 01, S. 31 - S34
ISSN: 2194-9379Online Volltext: dx.doi.org/ -
Entscheidungsfindung für die klinische Praxis : Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim MelanomIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 4, S. 8 - 12
ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE studyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1152P
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)In: Scientific Reports Jg. 6 (2016) S. 25208
ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access) -
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment : a pooled analysis of individual patient data from randomised trialsIn: The Lancet Oncology Jg. 17 (2016) Nr. 12, S. 1743 - 1754
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Final overall survival for KEYNOTE-002 : pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1107O
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaIn: European Journal of Cancer Jg. 67 (2016) S. 46 - 54
ISSN: 0959-8049Online Volltext: dx.doi.org/ (Open Access) -
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1137P
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
High TERT promoter mutation frequency in non-acral cutaneous metastatic melanomaIn: Pigment Cell and Melanoma Research Jg. 29 (2016) Nr. 5, S. 598 - 600
ISSN: 1755-1471; 1755-148XOnline Volltext: dx.doi.org/ -
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 19, S. 4848 - 4858
ISSN: 1078-0432Online Volltext: dx.doi.org/ -
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survivalIn: International Journal of Cancer Jg. 139 (2016) Nr. 6, S. 1297 - 1302
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access) -
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosisIn: Medicine Jg. 95 (2016) Nr. 29, S. e4332
ISSN: 0025-7974Online Volltext: dx.doi.org/ (Open Access) -
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsIn: The Oncologist Jg. 21 (2016) Nr. 10, S. 1230 - 1240
ISSN: 1083-7159Online Volltext: dx.doi.org/ (Open Access) -
Mapping of deletion breakpoints at the CDKN2A locus in melanoma : Detection of MTAP-ANRIL fusion transcriptsIn: OncoTarget Jg. 7 (2016) Nr. 13, S. 16490 - 16504
ISSN: 1949-2553Online Volltext: dx.doi.org/ -
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie Jg. 34 (2016) Nr. 1-2, S. 14 - 22
ISSN: 0723-6913 -
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research Jg. 76 (2016) Nr. 15, S. 4347 - 4358
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Molecular features of response to anti-PD-1 therapyIn: Chinese Clinical Oncology Jg. 5 (2016) Nr. 6, S. 74
ISSN: 2304-3865Online Volltext: dx.doi.org/ (Open Access) -
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyIn: European Journal of Cancer Jg. 60 (2016) S. 210 - 225
ISSN: 1879-0852Online Volltext: dx.doi.org/ -
Oncogene Status of an Interdigitating Dendritic Cell Sarcoma : Recurrent Mutations in NF1, TP53, and ARID2 Shared With MelanomaIn: The American Journal of Surgical Pathology Jg. 40 (2016) Nr. 12, S. 1721 - 1723
ISSN: 0147-5185Online Volltext: dx.doi.org/ -
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer Jg. 57 (2016) S. 112 - 117
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) : A pooled analysisIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1112PD
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanomaIn: International Journal of Cancer Jg. 138 (2016) Nr. 3, S. 698 - 704
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access) -
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanomaIn: European Journal of Cancer Jg. 59 (2016) S. 109 - 112
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Photoacoustic imaging of real-time oxygen changes in chronic leg ulcers after topical application of a haemoglobin spray : a pilot studyIn: Journal of Wound Care Jg. 25 (2016) Nr. 2, S. 87 - 91
ISSN: 0969-0700; 2052-2916Online Volltext: dx.doi.org/ -
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trialsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1134P
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ -
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyIn: Medicine Jg. 95 (2016) Nr. 46, S. e5375
ISSN: 0025-7974Online Volltext: dx.doi.org/ (Open Access) -
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabIn: European Journal of Cancer Jg. 64 (2016) S. 116 - 126
ISSN: 0959-8049Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopesIn: Scientific Reports Jg. 6 (2016) S. 24032
ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access) -
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaIn: OncoTarget Jg. 7 (2016) Nr. 9, S. 10117 - 10132
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma : results of a phase I dose escalation studyIn: ESMO Open Jg. 1 (2016) Nr. 4, S. e000068
ISSN: 2059-7029Online Volltext: dx.doi.org/ (Open Access) -
Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNAIn: OncoTarget Jg. 7 (2016) Nr. 37, S. 59115 - 59128
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Survival of patients with advanced metastatic melanoma: The impact of novel therapiesIn: European Journal of Cancer Jg. 53 (2016) S. 125 - 134
ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/ -
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology Jg. 127 (2016) Nr. 3, S. 435 - 444
ISSN: 1573-7373; 0167-594XOnline Volltext: dx.doi.org/ Online Volltext (Open Access) -
The Influence of HLA and KIR Genes on Malignant Melanoma Development and ProgressionIn: Archivum Immunologiae et Therapiae Experimentalis Jg. 64 (2016) Nr. Suppl. 1, S. 73 - 81
ISSN: 1661-4917; 0004-069XOnline Volltext: dx.doi.org/ -
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor geneIn: Science Translational Medicine Jg. 8 (2016) Nr. 369, S. 369ra177
ISSN: 1946-6234; 1946-6242Online Volltext: dx.doi.org/ -
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. LBA40
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Treatment patterns of advanced malignant melanoma (stage III–IV) – A review of current standards in EuropeIn: European Journal of Cancer Jg. 60 (2016) S. 179 - 189
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature Jg. 532 (2016) Nr. 7598, S. 250 - 254
ISSN: 0028-0836; 1476-4687Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Jg. 26 (2015) Nr. 3, S. 573 - 582
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Acquired BRAF inhibitor resistance : A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsIn: European Journal of Cancer Jg. 51 (2015) Nr. 18, S. 2792 - 2799
ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Actual practice of melanoma follow-up and treatment in Germany : results of a prospective, longitudinal cohort studyIn: British Journal of Dermatology Jg. 172 (2015) Nr. 6, S. 1646 - 1650
ISSN: 1365-2133Online Volltext: dx.doi.org/ -
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 13 (2015) Nr. Suppl. 2, S. 11
ISSN: 1610-0379; 1610-0387; 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Antitumor activity of miR-1280 in melanoma by regulation of SrcIn: Molecular Therapy Jg. 23 (2015) Nr. 1, S. 71 - 78
ISSN: 1525-0016Online Volltext: dx.doi.org/ (Open Access) -
Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banksIn: Clinical Chemistry and Laboratory Medicine Jg. 53 (2015) Nr. 12, S. 1927 - 1934
ISSN: 1437-4331; 1434-6621; 1437-8523Online Volltext: dx.doi.org/ -
CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survivalIn: Cancer Research Jg. 75 (2015) Nr. 9, S. 1897 - 1907
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ (Open Access) -
CEACAM1-4L promotes anchorage-independent growth in melanomaIn: Frontiers in Oncology Jg. 5 (2015) S. 234
ISSN: 2234-943XOnline Volltext: dx.doi.org/ (Open Access) -
Clinical application of noninvasive and nonradioactive determination of microscopic lymph node tumor status by multispectral optoacoustic imagingIn: Journal of Nuclear Medicine Jg. 56 (2015) Nr. Suppl. 3, S. 40
ISSN: 0161-5505 -
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaIn: The New England Journal of Medicine Jg. 373 (2015) Nr. 1, S. 23 - 34
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanomaIn: Experimental Dermatology Jg. 24 (2015) Nr. 9, S. 709 - 710
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v) : results of a phase 3, open-label, randomised trialIn: The Lancet Oncology Jg. 16 (2015) Nr. 13, S. 1389 - 1398
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue-based testingIn: European Journal of Cancer Jg. 51 (2015) Nr. Suppl. 3, S. S685
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma : a multicentre, double-blind, phase 3 randomised controlled trialIn: The Lancet Jg. 386 (2015) Nr. 9992, S. 444 - 451
ISSN: 0140-6736; 1474-547XOnline Volltext: dx.doi.org/ -
Die multispektraloptoakustische Tomographie (MSOT) zur nichtinvasiven Diagnostik des Schildwächterlymphknotens bei Patienten mit malignem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 13 (2015) Nr. 12, S. 1323
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Disease kinetics for decision-making in advanced melanoma : a call for scenario-driven strategy trialsIn: The Lancet Oncology Jg. 16 (2015) Nr. 13, S. e522 - e526
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Erratum : Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25In: Cell Research Jg. 25 (2015) Nr. 3, S. 399 - 400
ISSN: 1001-0602Online Volltext: dx.doi.org/ -
Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies : prospective randomized clinical trial to compare ICG-99mTc-nanocolloid hybrid tracer versus 99mTc-nanocolloidIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 42 (2015) Nr. 11, S. 1631 - 1638
ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ -
Expanded access programmes : patient interests versus clinical trial integrityIn: The Lancet Oncology Jg. 16 (2015) Nr. 1, S. 15 - 17
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Expectation-induced placebo responses fail to accelerate wound healing in healthy volunteers : results from a prospective controlled experimental trialIn: International Wound Journal Jg. 12 (2015) Nr. 6, S. 664 - 668
ISSN: 1742-4801; 1742-481XOnline Volltext: dx.doi.org/ -
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science Jg. 56 (2015) Nr. 10, S. 5854 - 5861
ISSN: 0146-0404Online Volltext: dx.doi.org/ (Open Access) -
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predispositionIn: International Journal of Cancer Jg. 136 (2015) Nr. 9, S. 2109 - 2119
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ -
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanomaIn: Nature Genetics Jg. 47 (2015) Nr. 9, S. 987 - 995
ISSN: 1061-4036; 1546-1718Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Genomic Classification of Cutaneous MelanomaIn: Cell Jg. 161 (2015) Nr. 7, S. 1681 - 1696
ISSN: 1097-4172Online Volltext: dx.doi.org/ (Open Access) -
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science Jg. 350 (2015) Nr. 6257, S. 207 - 211
ISSN: 0036-8075; 1095-9203Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaIn: European Journal of Cancer Jg. 51 (2015) Nr. 7, S. 833 - 840
ISSN: 1879-0852; 1879-2995Online Volltext: dx.doi.org/ -
Improved overall survival in melanoma with combined dabrafenib and trametinibIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 1, S. 30 - 39
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohortIn: OncoTarget Jg. 6 (2015) Nr. 13, S. 11683 - 11693
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Integrating first-line treatment options into clinical practice : What's new in advanced melanoma?In: Melanoma Research Jg. 25 (2015) Nr. 6, S. 461 - 469
ISSN: 1473-5636; 0960-8931Online Volltext: dx.doi.org/ -
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma : Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialIn: Journal of Clinical Oncology Jg. 33 (2015) Nr. 34, S. 4077 - 4084
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection : Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph NodesIn: JAMA Surgery Jg. 150 (2015) Nr. 7, S. 617 - 623
ISSN: 2168-6254; 2168-6262Online Volltext: dx.doi.org/ (Open Access) -
MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanomaIn: Pigment Cell and Melanoma Research Jg. 28 (2015) Nr. 6, S. 736 - 740
ISSN: 1755-148XOnline Volltext: dx.doi.org/ -
MelanomaIn: Nature Reviews Disease Primers Jg. 1 (2015) S. 15003
ISSN: 2056-676XOnline Volltext: dx.doi.org/ -
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imagingIn: Immunotherapy Jg. 7 (2015) Nr. 317, S. 317ra199
ISSN: 1750-7448; 1750-743XOnline Volltext: dx.doi.org/ -
Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulationsIn: Experimental Dermatology Jg. 24 (2015) Nr. 2, S. 155 - 157
ISSN: 1600-0625Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with IpilimumabIn: Clinical Cancer Research Jg. 21 (2015) Nr. 24, S. 5453 - 5459
ISSN: 1078-0432Online Volltext: dx.doi.org/ (Open Access) -
NEMO : A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapyIn: Cancer Research Jg. 75 (2015) Nr. Suppl. 14, S. B16
ISSN: 0008-5472Online Volltext: dx.doi.org/ -
Nachruf für Prof. Dr. med. Christiane Voit (Berlin)In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 13 (2015) Nr. 8, S. 851 - 852
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Nivolumab in previously untreated melanoma without BRAF mutationIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 4, S. 311 - 319
ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaIn: Journal of Translational Medicine Jg. 13 (2015) Nr. 1, S. 351
ISSN: 1479-5876Online Volltext: dx.doi.org/ (Open Access) -
Panel Sequencing MelanomasIn: The Journal of Investigative Dermatology Jg. 135 (2015) Nr. 2, S. 335 - 336
ISSN: 0022-202X; 1523-1747Online Volltext: dx.doi.org/ (Open Access) -
Pembrolizumab versus Ipilimumab in Advanced MelanomaIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 26, S. 2521 - 2532
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ -
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trialIn: The Lancet Oncology Jg. 16 (2015) Nr. 8, S. 908 - 918
ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ -
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaIn: Journal of Clinical Oncology Jg. 33 (2015) Nr. 17, S. 1889 - 1894
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patientsIn: International Journal of Cancer Jg. 136 (2015) Nr. 1, S. 138 - 151
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ -
Prolongation of QTc interval in HIV-infected individuals compared to the general population is not caused by antiretroviral therapyIn: Journal of the International AIDS Society Jg. 18 (2015) Nr. Suppl. 4, S. 20479
ISSN: 1758-2652Online Volltext: dx.doi.org/ (Open Access) -
Prospective evaluation of follow-up in melanoma patients in Germany : results of a multicentre and longitudinal studyIn: European Journal of Cancer Jg. 51 (2015) Nr. 5, S. 653 - 667
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology Jg. 26 (2015) Nr. 6, S. 1238 - 1244
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ -
ResponseIn: Journal of the National Cancer Institute Jg. 107 (2015) Nr. 4, S. djv051
ISSN: 0027-8874Online Volltext: dx.doi.org/ -
Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly womanIn: British Journal of Dermatology Jg. 172 (2015) Nr. 6, S. 1642 - 1645
ISSN: 0007-0963Online Volltext: dx.doi.org/ -
Systemic therapies for melanoma brain metastases : which drug for whom and when?In: Chinese Clinical Oncology Jg. 4 (2015) Nr. 2, S. 25 - 29
ISSN: 2304-3873Online Volltext: dx.doi.org/ -
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget Jg. 6 (2015) Nr. 34, S. 36041 - 36052
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells : a live-cell RNAi screen displays differential nucleus-derived phenotypesIn: Biotechnology Journal Jg. 10 (2015) Nr. 9, S. 1467 - 1477
ISSN: 1860-7314; 1860-6768Online Volltext: dx.doi.org/ -
The GERMELATOX DeCOG-trial : The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspectiveIn: European Journal of Cancer Jg. 51 (2015) Nr. Suppl. 3, S. S671 - S672
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974
ISSN: 0947-8965Online Volltext: dx.doi.org/ -
Treatment algorithms in stage IV melanomaIn: American Journal of Therapeutics Jg. 22 (2015) Nr. 1, S. 61 - 67
ISSN: 1536-3686; 1075-2765Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access) -
Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaIn: European Journal of Cancer Jg. 51 (2015) Nr. Suppl. 3, S. S663
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
VorwortIn: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 3, S. 1
ISSN: 2296-5262Online Volltext: dx.doi.org/ -
miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagyIn: OncoTarget Jg. 6 (2015) Nr. 5, S. 2966 - 2980
ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access) -
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma : a BioGenoMEL studyIn: Pigment Cell and Melanoma Research Jg. 27 (2014) Nr. 2, S. 234 - 243
ISSN: 1755-1471; 1755-148XOnline Volltext: dx.doi.org/ (Open Access) -
Angioplasmacellular hyperplasia - a new histopathologic clue for anogenital herpes simplex recidivans in immunocompromised patients?In: American Journal of Dermatopathology Jg. 36 (2014) Nr. 10, S. 822 - 826
ISSN: 0193-1091; 1533-0311Online Volltext: dx.doi.org/ -
Arbeitsgemeinschaft Dermatologische Onkologie – eine dermatologische ErfolgsgeschichteIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 12 (2014) Nr. Suppl. 4, S. 40 - 41
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Behandlungsalgorithmus bei Patienten mit malignem MelanomIn: Der Onkologe Jg. 20 (2014) Nr. 6, S. 533 - 534
ISSN: 0947-8965; 0947-8965Online Volltext: dx.doi.org/ -
Childhood Psoriasis : An Analysis of German Health Insurance DataIn: Pediatric Dermatology Jg. 31 (2014) Nr. 1, S. 8 - 13
ISSN: 1525-1470; 0736-8046Online Volltext: dx.doi.org/ -
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanomaIn: Clinical Cancer Research Jg. 20 (2014) Nr. 16, S. 4390 - 4399
ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ -
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinomaIn: The Oncologist Jg. 19 (2014) Nr. 8, S. 790 - 796
ISSN: 1549-490X; 1083-7159Online Volltext: dx.doi.org/ -
Clinical performance of the Nevisense system in cutaneous melanoma detection : an international, multicentre, prospective and blinded clinical trial on efficacy and safetyIn: British Journal of Dermatology Jg. 171 (2014) Nr. 5, S. 1099 - 1107
ISSN: 0007-0963; 1365-2133Online Volltext: dx.doi.org/ (Open Access) -
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaIn: The New England Journal of Medicine Jg. 371 (2014) Nr. 20, S. 1877 - 1888
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ (Open Access) -
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanomaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 41 (2014) Nr. 9, S. 1723 - 1731
ISSN: 1619-7089Online Volltext: dx.doi.org/ -
Die Photooptoakustische Tomographie zur nicht invasiven und nicht radioaktiven Bestimmung des Schildw € achterlymphknotenstatus bei MelanompatientenIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 12 (2014) Nr. Suppl. 3, S. 5 - 6
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Expression of stress ligands of the immunoreceptor NKG2D in melanoma : regulation and clinical significanceIn: European Journal of Cell Biology Jg. 93 (2014) Nr. 1-2, S. 49 - 54
ISSN: 0171-9335Online Volltext: dx.doi.org/ -
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : Quality-of-life analyses of the METRIC studyIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 700 - 706
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Genetic alterations and personalized medicine in melanoma: Progress and future prospectsIn: Journal of the National Cancer Institute Jg. 106 (2014) Nr. 2, S. djt435
ISSN: 1460-2105Online Volltext: dx.doi.org/ -
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology Jg. 27 (2014) Nr. 2, S. 175 - 183
ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ -
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research Jg. 20 (2014) Nr. 24, S. 6593 - 6604
ISSN: 1078-0432Online Volltext: dx.doi.org/ -
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trialIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 742 - 746
ISSN: 1569-8041Online Volltext: dx.doi.org/ -
Immunonkologie "Coming of Age" : die nächste Generation der Immun-Checkpoint-InhibitorenIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 4, S. 6 - 9
ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Immunonkologie «Coming of Age» - die nächste Generation der Immun-Checkpoint-InhibitorenIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 4, S. 6 - 9
ISSN: 2296-5262 -
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 8, S. 816 - 823
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Inherited variation in the PARP1 gene and survival from melanomaIn: International Journal of Cancer Jg. 135 (2014) Nr. 7, S. 1625 - 1633
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access) -
Isoform-specific function of CEACAM1 during tumorigenesis : CEACAM1-3S, a novel prognostic biomarker in malignant melanomaIn: Experimental Dermatology Jg. 23 (2014) Nr. 3, S. E45
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
MIKIE : A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomasIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. TPS9121
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Malignes MelanomIn: Der Onkologe Jg. 20 (2014) Nr. 6, S. 530 - 532
ISSN: 0947-8965Online Volltext: dx.doi.org/ -
Medikamentöse Systemtherapie des MelanomsIn: Der Onkologe Jg. 20 (2014) Nr. 6, S. 568 - 576
ISSN: 1433-0415Online Volltext: dx.doi.org/ -
Melanoma in 2013 : Melanoma - The run of success continuesIn: Nature Reviews Clinical Oncology Jg. 11 (2014) Nr. 2, S. 75 - 76
ISSN: 1759-4782Online Volltext: dx.doi.org/ -
Metastatic basal cell carcinoma : prognosis dependent on anatomic site and spread of diseaseIn: European Journal of Cancer Jg. 50 (2014) Nr. 4, S. 774 - 783
ISSN: 0959-8049; 1879-0852; 0014-2964; 1879-2995Online Volltext: dx.doi.org/ (Open Access) -
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma : Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cellsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 6, S. 1601 - 1609
ISSN: 1557-3265Online Volltext: dx.doi.org/ -
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans : A multicenter phase II DeCOG Trial with Long-Term Follow-UpIn: Clinical Cancer Research Jg. 20 (2014) Nr. 2, S. 499 - 510
ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ -
Peripheral immune signatures and survival in stage IV melanomaIn: Cancer Research Jg. 74 (2014) Nr. 19 Suppl., S. 2547
ISSN: 0008-5472Online Volltext: dx.doi.org/ -
Primary tumor versus metastasis : new experimental models for studies on cancer cell homing and metastasis in melanomaIn: Pigment Cell and Melanoma Research Jg. 27 (2014) Nr. 2, S. 309 - 316
ISSN: 1755-148XOnline Volltext: dx.doi.org/ -
Quality assurance for care of melanoma patients based on guideline-derived quality indicators and certificationIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 12 (2014) Nr. 2, S. 139 - 147
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Reply to M. Perier-Muzet et al [Safety and Management of New Primary Melanomas During Receipt of BRAF Inhibitors ]In: Journal of Clinical Oncology Jg. 32 (2014) Nr. 28, S. 3203 - 3204
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology Jg. 28 (2014) Nr. 12, S. 1685 - 1689
ISSN: 1468-3083Online Volltext: dx.doi.org/ -
STAT3 single nucleotide polymorphism rs4796793 SNP does not correlate with response to adjuvant IFNα therapy in stage III melanoma patientsIn: Frontiers in Medicine Jg. 1 (2014) Nr. 47,
ISSN: 2296-858XOnline Volltext: dx.doi.org/ (Open Access) -
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) : extended follow-up of a phase 3, randomised, open-label studyIn: The Lancet Oncology Jg. 15 (2014) Nr. 3, S. 323 - 332
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutationIn: The New England Journal of Medicine Jg. 371 (2014) Nr. 9, S. 880 - 882
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ -
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine Jg. 3 (2014) Nr. 5, S. 1284 - 1293
ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access) -
Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsIn: The Lancet Oncology Jg. 15 (2014) Nr. 3, S. 297 - 304
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute Jg. 106 (2014) Nr. 9,
ISSN: 1460-2105; 0027-8874Online Volltext: dx.doi.org/ -
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology Jg. 27 (2014) Nr. 4, S. 502 - 508
ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ (Open Access) -
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaIn: Cancer Discovery Jg. 4 (2014) Nr. 1, S. 94 - 109
ISSN: 2159-8274; 2159-8290Online Volltext: dx.doi.org/ -
The impact of the immune system on tumor : angiogenesis and vascular remodelingIn: Frontiers in Oncology Jg. 4 (2014) S. 69
ISSN: 2234-943XOnline Volltext: dx.doi.org/ (Open Access) -
The validity of circulating microRNAs in oncology : Five years of challenges and contradictionsIn: Molecular Oncology Jg. 8 (2014) Nr. 4, S. 819 - 829
ISSN: 1878-0261Online Volltext: dx.doi.org/ (Open Access) -
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanomaIn: Nature Jg. 507 (2014) Nr. 7490, S. 109 - 113
ISSN: 0028-0836; 1476-4687Online Volltext: dx.doi.org/ -
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition : MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsIn: European Journal of Cancer Jg. 50 (2014) Nr. 2, S. 406 - 410
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF InhibitionIn: Cancer Discovery Jg. 3 (2013) Nr. 3, S. 351 - 362
ISSN: 2159-8274; 2159-8290Online Volltext: dx.doi.org/ -
Analysis of dermatologic events in vemurafenib-treated patients with melanomaIn: The Oncologist Jg. 18 (2013) Nr. 3, S. 314 - 322
ISSN: 1549-490X; 1083-7159; 2159-8401Online Volltext: dx.doi.org/ -
Autoimmuno-hypophysitis, Autoimmuno-colitis and Autoimmuno-hepatitis in a Patient with metastatic Melanoma during Therapy with CTLA-4 Antibody IpilimumabIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 11 (2013) Nr. 9, S. 932
ISSN: 1610-0379; 1610-0387 -
B-type natriuretic peptide elevation is more frequent in HIV plus patients compared to the general populationIn: Antiviral Therapy Jg. 18 (2013) Nr. Suppl. 3, S. A41 - A42
ISSN: 1359-6535 -
Cognitive factors mediate placebo responses in patients with house dust mite allergyIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e79576
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology Jg. 31 (2013) Nr. 30, S. 3844 - 3845
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332
ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ -
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research Jg. 19 (2013) Nr. 12, S. 3143 - 3152
ISSN: 1557-3265; 1557-3265Online Volltext: dx.doi.org/ -
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.In: The Journal of Investigative Dermatology Jg. 133 (2013) Nr. 6, S. 1610 - 1619
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ (Open Access) -
Dermatologic adverse events associated with afatinib : An oral ErbB family blockerIn: Expert Review of Anticancer Therapy Jg. 13 (2013) Nr. 6, S. 721 - 728
ISSN: 1473-7140; 1744-8328Online Volltext: dx.doi.org/ -
Die neue S3-Leitlinie "melanom" : Das Wichtigste für die PraxisIn: Best Practice Onkologie Jg. 8 (2013) Nr. 2, S. 40 - 48
ISSN: 0946-4565; 1862-8559Online Volltext: dx.doi.org/ -
Die neue S3-leitlinie "Diagnostik, therapie und nachsorge des malignen melanoms" : Wie soll das staging durchgeführt werden?In: Haut Jg. 24 (2013) Nr. 3, S. 124 - 128
ISSN: 0938-2216 -
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease controlIn: Clinical Cancer Research Jg. 19 (2013) Nr. 8, S. 2232 - 2239
ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ -
Framingham risk score and cardiovascular risk profiles in HIV+ patients and HIV- controls differ by sexIn: European Heart Journal Jg. 34 (2013) Nr. Suppl. 1, S. P5164
ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 - 143
ISBN: 978-3-934359-44-4 ISSN: 0944-6060; 1869-3881Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Intracerebral metastases of malignant melanoma and their recurrences : a clinical analysisIn: Clinical Neurology and Neurosurgery Jg. 115 (2013) Nr. 9, S. 1721 - 1728
ISSN: 1872-6968; 0303-8467Online Volltext: dx.doi.org/ -
Isolated cerebral susceptibility artefacts in patients with malignant melanoma : Metastasis or not?In: European Radiology Jg. 23 (2013) Nr. 9, S. 2622 - 2627
ISSN: 0938-7994; 1432-1084Online Volltext: dx.doi.org/ -
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 11 (2013) Nr. 9, S. 952 - 952
ISSN: 1610-0379; 1610-0387; 0301-0481; 1563-2571 -
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology Jg. 8 (2013) S. 87
ISSN: 1746-1596Online Volltext: dx.doi.org/ (Open Access) -
Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanomaIn: Experimental Dermatology Jg. 22 (2013) Nr. 11, S. 757 - 759
ISSN: 1600-0625; 0906-6705Online Volltext: dx.doi.org/ -
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 studyIn: The Lancet Oncology Jg. 14 (2013) Nr. 3, S. 249 - 256
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Malignes melanom S3-leitlinie "Diagnostik, Therapie und Nachsorge des Melanoms"In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 11 (2013) Nr. Suppl. 6, S. 1 - 116; 1 - 126
ISSN: 1610-0387; 1610-0379; 0301-0481; 1563-2571Online Volltext: dx.doi.org/ (Open Access) -
MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2In: Cancer Letters Jg. 341 (2013) Nr. 2, S. 240 - 247
ISSN: 1872-7980; 0304-3835Online Volltext: dx.doi.org/ -
MiR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genesIn: The Journal of Investigative Dermatology Jg. 133 (2013) Nr. 3, S. 768 - 775
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ (Open Access) -
Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. Lunge, Niere, MelanomIn: Der Onkologe Jg. 19 (2013) Nr. 10, S. 821 - 834
ISSN: 1433-0415Online Volltext: dx.doi.org/ -
Neuropilin-1 Deficiency on CD4+Foxp3+Regulatory T Cells Modulates Tumor Angiogenesis and Impaires Tumor Growth in MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 11 (2013) Nr. Suppl. S7, S. 30
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Neuropilin-1 is a key mediator of VEGF-dependent Treg migration to tumorsIn: International Journal of Molecular Medicine Jg. 32 (2013) Nr. Suppl. 1, S. S36
ISSN: 1107-3756; 1791-244X -
New developments in biomarkers for melanomaIn: Current Opinion in Oncology Jg. 25 (2013) Nr. 2, S. 145 - 151
ISSN: 1040-8746; 1531-703XOnline Volltext: dx.doi.org/ -
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaIn: Journal of Clinical Oncology Jg. 31 (2013) Nr. 26, S. 3205 - 3211
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Prevalence of cardiovascular diseases in HIV-infected outpatients: Results from a prospective, multicenter cohort studyIn: Clinical Research in Cardiology Jg. 102 (2013) Nr. 3, S. 203 - 213
ISSN: 1861-0692; 1861-0684; 0300-5860; 1435-1285Online Volltext: dx.doi.org/ -
Psychotropic drugs are prescribed more frequently in HIV-positive patients compared to the general population. Data from two German prospective cohorts : Heinz Nixdorf Recall Study and HIV HEART StudyIn: Antiviral Therapy Jg. 18 (2013) Nr. Suppl. 3, S. A77 - A78
ISSN: 1359-6535 -
Rapid progression of a splenic aneurysm due to segmental arterial mediolysis: : a rare cause of acute pancreatitisIn: Pancreatology Jg. 13 (2013) Nr. 5, S. 553 - 556
ISSN: 1424-3903; 1424-3911Online Volltext: dx.doi.org/ -
Risk loci for coronary artery calcification replicated at 9p21 and 6q24 in the Heinz Nixdorf Recall StudyIn: BMC Medical Genetics Jg. 14 (2013) Nr. 1, S. 23
ISSN: 1471-2350Online Volltext: dx.doi.org/ (Open Access) -
S3-Guideline "diagnosis, therapy and follow-up of melanoma" - short versionIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 11 (2013) Nr. 6, S. 593 - 602
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma : A phase 2 double-blind randomised studyIn: The Lancet Oncology Jg. 14 (2013) Nr. 8, S. 733 - 740
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e80354
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismIn: Proceedings of the National Academy of Sciences of the United States of America Jg. 110 (2013) Nr. 43, S. 17426 - 17431
ISSN: 1091-6490; 0027-8424Online Volltext: dx.doi.org/ -
TERT promoter mutations in familial and sporadic melanomaIn: Science Jg. 339 (2013) Nr. 6122, S. 959 - 961
ISSN: 1095-9203; 0036-8075Online Volltext: dx.doi.org/ -
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: The British Journal of Cancer: BJC Jg. 109 (2013) Nr. 2, S. 497 - 501
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access) -
Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell -based vaccinationIn: Cancer Research Jg. 73 (2013) Nr. 1, S. 19 - 29
ISSN: 0008-5472; 1538-7445; 0099-7013; 0099-7374Online Volltext: dx.doi.org/ -
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.In: Cancer Medicine Jg. 2 (2013) Nr. 1, S. 76 - 85
ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access) -
The price of tumor control : an analysis of rare side effects of Anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkIn: PLoS ONE Jg. 8 (2013) Nr. 1, S. e53745
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Tumor regression and sirolimus-based therapy in lung transplantationIn: The Journal of Heart and Lung Transplantation Jg. 32 (2013) Nr. 9, S. 938 - 939
ISSN: 1053-2498; 1557-3117Online Volltext: dx.doi.org/ -
Valvular manifestations of human immunodeficiency virus infection - Results from the prospective, multicenter HIV-HEART studyIn: Journal of Cardiovascular Medicine Jg. 14 (2013) Nr. 10, S. 733 - 739
ISSN: 1558-2035; 1558-2035Online Volltext: dx.doi.org/ -
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsIn: Science Signaling Jg. 6 (2013) Nr. 260,
ISSN: 1945-0877; 1937-9145; 1525-8882Online Volltext: dx.doi.org/ -
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer Jg. 133 (2013) Nr. 7, S. 1653 - 1663
ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ -
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research Jg. 73 (2013) Nr. 8 Suppl., S. 4714
ISSN: 0008-5472Online Volltext: dx.doi.org/ -
VorwortIn: Onkologie Jg. 36 (2013) Nr. Suppl. 4, S. 1
ISSN: 0378-584X; 1423-0240; 2296-5262; 2296-5270Online Volltext: dx.doi.org/ -
β-Blocker use and all-cause mortality of melanoma patients : results from a population-based Dutch cohort studyIn: European Journal of Cancer Jg. 49 (2013) Nr. 18, S. 3863 - 3871
ISSN: 0959-8049; 1879-0852; 1879-2995; 0014-2964Online Volltext: dx.doi.org/ -
A Landscape of Driver Mutations in MelanomaIn: Cell Jg. 150 (2012) Nr. 2, S. 251 - 263
ISSN: 0092-8674; 1097-4172Online Volltext: dx.doi.org/ -
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 10, S. x104 - x108
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ Online Volltext -
Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes : a retrospective analysis in 221 patients with malignant melanoma AJCC Stages i and IIIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 1, S. 79 - 85
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Association Between Sentinel Lymph Node Excision With or Without Preoperative SPECT/CT and Metastatic Node Detection and Disease-Free Survival in MelanomaIn: JAMA: Journal of the American Medical Association Jg. 308 (2012) Nr. 10, S. 1007 - 1014
ISSN: 1538-3598; 0098-7484Online Volltext: dx.doi.org/ -
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. 19, S. 2375 - 2383
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Brain metastasis : Opportunity for drug development?In: Current Opinion in Neurology Jg. 25 (2012) Nr. 6, S. 786 - 794
ISSN: 1473-6551Online Volltext: dx.doi.org/ -
Brain natriuretic peptide (BNP) : A general mortality predictor in HIV-infected patients? - Results from the 5 year follow-up of the HIV-HEART trialIn: European Heart Journal Jg. 33 (2012) Nr. Suppl. 1, S. 337
ISSN: 0195-668X; 1522-9645 -
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 10 (2012) Nr. 5, S. 319 - 325
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology Jg. 13 (2012) Nr. 11, S. 1087 - 1095
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Detection of abacavir hypersensitivity by ELISpot methodIn: Inflammation & Allergy: Drug Targets Jg. 11 (2012) Nr. 3, S. 227 - 234
ISSN: 2212-4055; 1871-5281Online Volltext: dx.doi.org/ -
EORTC Melanoma Group achievementsIn: European Journal of Cancer / EJC Supplements Jg. 10 (2012) Nr. 1, S. 112 - 119
ISSN: 1359-6349; 1878-1217Online Volltext: dx.doi.org/ -
Fluoreszenz-Markierung mittels Indocyanin-Grün bei der Sentinel-Lymphknoten-Exstirpation in der DermatoonkologieIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 10 (2012) Nr. 1, S. 51 - 58
ISSN: 1610-0387Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ -
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasisIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. 15, S. 1835 - 1841
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Gegen den Hautkrebs : Forschung zur Überwindung immuntherapeutischer Hürden beim malignen MelanomIn: Unikate: Berichte aus Forschung und Lehre (2012) Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 32 - 41
ISBN: 978-3-934359-42-0 ISSN: 0944-6060; 1869-3881Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Good shedder or bad shedder : the influence of skin diseases on forensic DNA analysis from epithelial abrasionsIn: International Journal of Legal Medicine Jg. 126 (2012) Nr. 1, S. 179 - 183
ISSN: 0937-9827; 1437-1596Online Volltext: dx.doi.org/ -
Immuntherapie des MelanomsIn: Der Hautarzt Jg. 63 (2012) Nr. 12, S. 952 - 960
ISSN: 1432-1173Online Volltext: dx.doi.org/ -
Immuntherapie des MelanomsIn: Der Onkologe Jg. 18 (2012) Nr. 9, S. 801 - 807
ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/ -
Improved survival with MEK inhibition in BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 367 (2012) Nr. 2, S. 107 - 114
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ -
Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and TherapyIn: PLoS ONE Jg. 7 (2012) Nr. 11, S. 0050692
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Inherited variants in the MC1R gene and survival from cutaneous melanoma : A BioGenoMEL studyIn: Pigment Cell and Melanoma Research Jg. 25 (2012) Nr. 3, S. 384 - 394
ISSN: 1755-148X; 1755-1471Online Volltext: dx.doi.org/ -
Integrin genes and susceptibility to human melanomaIn: Mutagenesis Jg. 27 (2012) Nr. 3, S. 367 - 373
ISSN: 1464-3804; 0267-8357Online Volltext: dx.doi.org/ -
Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1In: AIDS Jg. 26 (2012) Nr. 17, S. 2145 - 2153
ISSN: 1473-5571Online Volltext: dx.doi.org/ -
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III MelanomaIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. 31, S. 3810 - 3818
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
MEK inhibition in BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 367 (2012) Nr. 14, S. 1365
ISSN: 1533-4406Online Volltext: dx.doi.org/ -
Melanoma genome sequencing reveals frequent PREX2 mutationsIn: Nature Jg. 485 (2012) Nr. 7399, S. 502 - 506
ISSN: 0028-0836; 1476-4687Online Volltext: dx.doi.org/ -
Neuropilin 1 deficiency on CD4⁺Foxp3⁺ regulatory T cells impairs mouse melanoma growthIn: Journal of Experimental Medicine Jg. 209 (2012) Nr. 11, S. 2001 - 2016
ISSN: 0022-1007; 1540-9538Online Volltext: dx.doi.org/ (Open Access) -
PHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomasIn: American Journal of Dermatopathology Jg. 34 (2012) Nr. 3, S. 266 - 269
ISSN: 1533-0311; 0193-1091Online Volltext: dx.doi.org/ -
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology Jg. 148 (2012) Nr. 3, S. 357 - 361
ISSN: 1538-3652Online Volltext: dx.doi.org/ -
Psoriasis im Kindes- und Jugendalter : Eine bundesweite Ärztebefragung zur Versorgungssituation in DeutschlandIn: Der Hautarzt Jg. 63 (2012) Nr. 10, S. 801 - 807
ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ -
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. 3, S. 316 - 321
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Radio-guided surgery : Advantages of a new portable γ-camera (Sentinella®) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignanciesIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 3, S. 308 - 313
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma : Final results of the EORTC 18021 studyIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. Suppl. 15, S. 8532
ISSN: 0732-183X; 1527-7755 -
Reliability and cost-effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia : A retrospective analysis in patients with malignant melanoma AJCC stage IIIIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 2, S. 200 - 206
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 10 (2012) Nr. 7, S. 475 - 486
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Skin Examination Behavior : The Role of Melanoma History, Skin Type, Psychosocial Factors, and Region of Residence in Determining Clinical and Self-conducted Skin ExaminationIn: Archives of Dermatology Jg. 148 (2012) Nr. 10, S. 1142 - 1151
ISSN: 0003-987X; 1538-3652Online Volltext: dx.doi.org/ -
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinicsIn: HIV Medicine Jg. 13 (2012) Nr. 9, S. 533 - 540
ISSN: 1464-2662; 1468-1293Online Volltext: dx.doi.org/ -
T-cell mediated immune responses induced in ret transgenic mouse model of malignant melanomaIn: Cancers Jg. 4 (2012) Nr. 2, S. 490 - 503
ISSN: 2072-6694Online Volltext: dx.doi.org/ -
The efficiency of human cytomegalovirus pp65₄₉₅₋₅₀₃ CD8 ⁺T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidasesIn: The Journal of Immunology Jg. 189 (2012) Nr. 2, S. 529 - 538
ISSN: 1550-6606; 0022-1767Online Volltext: dx.doi.org/ -
Treatment of Severe Psoriasis With Etanercept in a Pancreas-Kidney Transplant RecipientIn: Transplantation Proceedings Jg. 44 (2012) Nr. 9, S. 2776 - 2777
ISSN: 0041-1345; 1873-2623Online Volltext: dx.doi.org/ -
Trial design on prophylaxis and treatment of brain metastases : Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012In: European Journal of Cancer Jg. 48 (2012) Nr. 18, S. 3439 - 3447
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2DIn: Cancer Research Jg. 72 (2012) Nr. 2, S. 460 - 471
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Ulceration and stage are predictive of interferon efficacy in melanoma : results of the phase III adjuvant trials EORTC 18952 and EORTC 18991In: European Journal of Cancer Jg. 48 (2012) Nr. 2, S. 218 - 225
ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/ -
Vitamin A metabolism in benign and malignant melanocytic skin cells : Importance of lecithin/retinol acyltransferase and RPE65In: Journal of Cellular Physiology Jg. 227 (2012) Nr. 2, S. 718 - 728
ISSN: 0021-9541; 1097-4652Online Volltext: dx.doi.org/ -
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-upIn: European Journal of Cancer Jg. 47 (2011) Nr. 13, S. 1977 - 1989
ISSN: 0964-1947; 1879-0852Online Volltext: dx.doi.org/ -
A randomised, phase II study of intetumumab, an anti-α v-integrin mAb, alone and with dacarbazine in stage IV melanomaIn: The British Journal of Cancer: BJC Jg. 105 (2011) Nr. 3, S. 346 - 352
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access) -
Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignanciesIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 10, S. 1213 - 1221
ISSN: 1468-3083Online Volltext: dx.doi.org/ -
Arbeitsgemeinschaft Dermatologische Onkologie (ADO) : Gezielte Blockade des mutierten BRAF führt zu Überlebensvorteil bei Patienten mit metastasiertem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. 4, S. 340
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and SurvivalIn: PLoS ONE Jg. 6 (2011) Nr. 9,
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Behavioural conditioning as the mediator of placebo responses in the immune systemIn: Philosophical Transactions of the Royal Society B: Biological Sciences Jg. 366 (2011) Nr. 1572, S. 1799 - 1807
ISSN: 1471-2970Online Volltext: dx.doi.org/ -
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma : One step forward for overcoming anti-angiogenic drug resistance?In: Molecular Oncology Jg. 5 (2011) Nr. 2, S. 137 - 149
ISSN: 1574-7891Online Volltext: dx.doi.org/ -
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma modelIn: Proceedings of the National Academy of Sciences of the United States of America Jg. 108 (2011) Nr. 41, S. 17111 - 17116
ISSN: 1091-6490; 0027-8424Online Volltext: dx.doi.org/ -
Cutaneous melanoma : A model to study cancer metastasisIn: Journal of Surgical Oncology Jg. 103 (2011) Nr. 6, S. 538 - 549
ISSN: 0022-4790; 1096-9098Online Volltext: dx.doi.org/ -
DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanomaIn: Journal of Clinical Oncology Jg. 29 (2011) Nr. 15_suppl, S. TPS232
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Die Sklerotherapie mit Polidocanolschaum ist eine neue und effektive Behandlung von postoperativen Lymphozelen und LymphorrhoeIn: Vasomed Jg. 23 (2011) Nr. 5, S. 252
ISSN: 0935-9729 -
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift Jg. 136 (2011) Nr. 1-2, S. 39 - 44
ISSN: 1439-4413; 1437-5982; 0012-0472Online Volltext: dx.doi.org/ -
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanomaIn: The Journal of Investigative Dermatology Jg. 131 (2011) Nr. 6, S. 1280 - 1290
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ (Open Access) -
Endogenous μ-opioid peptides modulate immune response towards malignant melanomaIn: Experimental Dermatology Jg. 20 (2011) Nr. 1, S. 24 - 28
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanomaIn: Carcinogenesis Jg. 32 (2011) Nr. 10, S. 1467 - 1473
ISSN: 1460-2180; 0143-3334Online Volltext: dx.doi.org/ -
Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert surveyIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. 2, S. 116 - 121
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Expectation-induced Placebo effects in Wound healing processes : First results from a prospective clinical StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. 11, S. 984 - 984
ISSN: 1610-0379; 1610-0387 -
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma : Final results of a randomised phase III study (EORTC 18032)In: European Journal of Cancer Jg. 47 (2011) Nr. 10, S. 1476 - 1483
ISSN: 0964-1947; 1879-0852Online Volltext: dx.doi.org/ -
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary AdenocarcinomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 3, S. 432 - 438
ISSN: 1556-1380; 1556-0864Online Volltext: dx.doi.org/ (Open Access) -
Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationIn: The New England Journal of Medicine Jg. 364 (2011) Nr. 26, S. 2507 - 2516
ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ -
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genesIn: Journal of Clinical Oncology Jg. 29 (2011) Nr. 15_suppl, S. 8518
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Investigation of adhesion of modern wound dressings : a comparative analysis of 56 different wound dressingsIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 8, S. 933 - 939
ISSN: 1468-3083Online Volltext: dx.doi.org/ -
Moderne Pharmakotherapie des malignen MelanomsIn: Der Internist Jg. 52 (2011) Nr. 6, S. 756 - 764
ISSN: 0020-9554Online Volltext: dx.doi.org/ -
Mucosal melanomas of the head and neck : New aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitorsIn: Melanoma Research Jg. 21 (2011) Nr. 6, S. 475 - 482
ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/ -
Nodular scabies: Hypersensitivity reaction or infection?In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. 10, S. 840 - 841
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanomaIn: Cancer Jg. 117 (2011) Nr. 8, S. 1697 - 1703
ISSN: 1934-662X; 1097-0142Online Volltext: dx.doi.org/ -
P4 Vorschlag für Posterpreis Medizin : Beeinflussung der Wundheilung durch Placeboeffekte: Erste Resultate einer prospektiven klinischen UntersuchungIn: Zeitschrift für Wundheilung Jg. 16 (2011) Nr. Suppl. B, S. 92
ISSN: 1439-670X -
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapyIn: Journal of Clinical Oncology Jg. 29 (2011) Nr. 15_suppl, S. 8520
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice : A multicentre Dermatologic Cooperative Oncology Group trialIn: Melanoma Research Jg. 21 (2011) Nr. 6, S. 516 - 523
ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/ -
Psoriasis therapy with Rtanercept in a Kidney and Pancreas transplant PatientsIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. Suppl. 1, S. 213
ISSN: 1610-0379; 1610-0387; 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma : A retrospective analysis in 300 patients with malignant melanoma AJCC Stages i and IIIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 3, S. 306 - 310
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaTIn: Experimental Dermatology Jg. 20 (2011) Nr. 4, S. 373 - 375
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ (Open Access) -
Rosacea in Children - A Case ReportIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. Suppl. 1, S. 240 - 240
ISSN: 1610-0379; 1610-0387 -
Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel : Erste Resultate einer klinischen UntersuchungIn: Der Hautarzt Jg. 62 (2011) Nr. 4, S. 280 - 286
ISSN: 1432-1173Online Volltext: dx.doi.org/ -
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Jg. 22 (2011) Nr. 7, S. 1667 - 1674
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ -
The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma CellsIn: The Journal of Investigative Dermatology Jg. 131 (2011) Nr. 2, S. 468 - 479
ISSN: 1523-1747; 0022-202XOnline Volltext: dx.doi.org/ (Open Access) -
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanomaIn: Pigment Cell & Melanoma Research Jg. 24 (2011) Nr. 4, S. 714 - 723
ISSN: 1755-148XOnline Volltext: dx.doi.org/ -
Adjuvant pegylated interferon α-2b therapy for melanomaIn: Oncology Letters Jg. 1 (2010) Nr. 2, S. 237 - 241
ISSN: 1792-1082Online Volltext: dx.doi.org/ -
Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumorsIn: The Journal of Investigative Dermatology Jg. 130 (2010) Nr. 12, S. 2844 - 2848
ISSN: 0022-202X; 1523-1747Online Volltext: dx.doi.org/ -
Bacterial colonization of chronic leg ulcers : current results compared with data 5 years ago in a specialized dermatology departmentIn: Journal of the European Academy of Dermatology and Venereology Jg. 24 (2010) Nr. 9, S. 1017 - 1025
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccineIn: Cancer Immunology, Immunotherapy Jg. 59 (2010) Nr. 6, S. 863 - 873
ISSN: 0340-7004; 1432-0851Online Volltext: dx.doi.org/ -
Diagnostik des malignen MelanomsIn: Der Onkologe Jg. 16 (2010) Nr. 12, S. 1121 - 1130
ISSN: 0947-8965Online Volltext: dx.doi.org/ -
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cellsIn: Molecular Immunology Jg. 47 (2010) Nr. 4, S. 678 - 684
ISSN: 0161-5890Online Volltext: dx.doi.org/ -
Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cellsIn: Journal of Clinical Oncology Jg. 28 (2010) Nr. Suppl. 15, S. e19027
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness : Results of a Randomized Phase III DeCOG TrialIn: Journal of Clinical Oncology Jg. 28 (2010) Nr. 5, S. 841 - 846
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Endoprotease Profiling with Double-Tagged Peptide Substrates : A New Diagnostic Approach in OncologyIn: Clinical Chemistry Jg. 56 (2010) Nr. 2, S. 272 - 280
ISSN: 0009-9147; 1530-8561Online Volltext: dx.doi.org/ -
Facial variant of eruptive vellus hair cysts : A case report and brief review of the literatureIn: Kosmetische Medizin Jg. 31 (2010) Nr. 4, S. 200 - 203
ISSN: 1430-4031 -
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapyIn: European Journal of Immunology Jg. 40 (2010) Nr. 6, S. 1786 - 1794
ISSN: 0014-2980Online Volltext: dx.doi.org/ -
Genetic and morphologic features for melanoma classificationIn: Pigment Cell and Melanoma Research Jg. 23 (2010) Nr. 6, S. 763 - 770
ISSN: 1755-1471; 1755-148XOnline Volltext: dx.doi.org/ -
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaIn: The New England Journal of Medicine Jg. 363 (2010) Nr. 8, S. 711 - 723
ISSN: 0028-4793; 1533-4406Online Volltext: dx.doi.org/ -
Ipilimumab efficacy and safety in patients with advanced melanoma : a retrospective analysis of HLA subtype from four trialsIn: Cancer Immunology: a Journal of the Academy of Cancer Immunology Jg. 10 (2010) Nr. 1, S. 9
ISSN: 1424-9634(Open Access) -
Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging studyIn: The Lancet Oncology Jg. 11 (2010) Nr. 2, S. 155 - 164
ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ -
Klippel-Trénaunay-Syndrom – eine seltene Ursache eines chronischen Ulcus crurisIn: Medizinische Klinik Jg. 105 (2010) Nr. 11, S. 841 - 844
ISSN: 0723-5003Online Volltext: dx.doi.org/ -
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeIn: The British Journal of Cancer: BJC Jg. 103 (2010) Nr. 6, S. 820 - 826
ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access) -
Melanoma risk factors, perceived threat and intentional tanning : an international online surveyIn: European Journal of Cancer Prevention Jg. 19 (2010) Nr. 3, S. 216 - 226
ISSN: 0959-8278; 1473-5709Online Volltext: dx.doi.org/ -
Mixed effect modelling of proteomic mass spectrometry data by using Gaussian mixturesIn: Journal of the Royal Statistical Society: Series C (Applied Statistics) Jg. 59 (2010) S. 617 - 633
ISSN: 0035-9254; 1467-9876Online Volltext: dx.doi.org/ -
Multicentre study on standardisation of melanoma cell culture : An initiative of the German Melanoma Research NetworkIn: Pigment Cell and Melanoma Research Jg. 23 (2010) Nr. 2, S. 296 - 298
ISSN: 1755-148X; 1755-1471Online Volltext: dx.doi.org/ -
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cellsIn: Blood Jg. 116 (2010) Nr. 9, S. 1454 - 1459
ISSN: 0006-4971; 1528-0020Online Volltext: dx.doi.org/ -
PGE2 Transiently Enhances DC Expression of CCR7 but Inhibits the Ability of DCs to Produce CCL19 and Attract Naïve T cellsIn: Clinical Immunology Jg. 135 (2010) S. S100
ISSN: 1521-6616Online Volltext: dx.doi.org/ -
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs Jg. 19 (2010) Nr. 11, S. 1439 - 1449
ISSN: 1354-3784; 1744-7658Online Volltext: dx.doi.org/ -
Pegylated interferons : Prospects for the use in the adjuvant and palliative therapy of metastatic melanomaIn: European Journal of Cancer Jg. 46 (2010) Nr. 1, S. 41 - 46
ISSN: 0959-8049Online Volltext: dx.doi.org/ -
Perianale Ulzerationen durch KaliumpermanganatbäderIn: Der Hautarzt Jg. 61 (2010) Nr. 5, S. 435 - 438
ISSN: 0017-8470Online Volltext: dx.doi.org/ -
Photopheresis in pediatric patients with low-body weight using the UVAR XTS systemIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 8 (2010) Nr. 1, S. 32 - 37
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphoceleIn: Journal of the European Academy of Dermatology and Venereology Jg. 24 (2010) Nr. 8, S. 904 - 909
ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ -
Polymorphisms in the CD28/CTLA4/ICOS genes : role in malignant melanoma susceptibility and prognosis?In: Cancer Immunology, Immunotherapy Jg. 59 (2010) Nr. 2, S. 303
ISSN: 0340-7004; 1432-0851Online Volltext: dx.doi.org/ -
Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online StudyIn: Cancer Epidemiology, Biomarkers & Prevention Jg. 19 (2010) Nr. 9, S. 2199 - 2210
ISSN: 1055-9965; 1538-7755Online Volltext: dx.doi.org/ -
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanomaIn: Journal of Experimental Medicine Jg. 207 (2010) Nr. 3, S. 491 - 503
ISSN: 0022-1007; 1540-9538Online Volltext: dx.doi.org/ (Open Access) -
Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide LibrariesIn: PLoS ONE Jg. 5 (2010) Nr. 11, S. e14137
ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access) -
Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanomaIn: Mutation Research: Genetic Toxicology and Environmental Mutagenesis Jg. 702 (2010) Nr. 1, S. 8 - 16
ISSN: 1383-5718; 1879-3592; 1388-2120Online Volltext: dx.doi.org/ -
Somatic alterations in the melanoma genome : a high-resolution array-based comparative genomic hybridization studyIn: Genes, Chromosomes and Cancer Jg. 49 (2010) Nr. 8, S. 733 - 745
ISSN: 1045-2257; 1098-2264Online Volltext: dx.doi.org/ -
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Journal of Clinical Oncology Jg. 28 (2010) Nr. Suppl. 15, S. 8526
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Steroid-induced Periorificial Dermatitis in Children—Clinical Features and Response to Azelaic AcidIn: Pediatric Dermatology Jg. 27 (2010) Nr. 2, S. 137 - 142
ISSN: 0736-8046; 1525-1470Online Volltext: dx.doi.org/ -
Systemic allergic contact dermatitis from intravenous piritramideIn: Allergy Jg. 65 (2010) Nr. 9, S. 1203 - 1204
ISSN: 0105-4538; 1398-9995Online Volltext: dx.doi.org/ -
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology Jg. 37 (2010) Nr. 5, S. 485 - 498
ISSN: 0093-7754; 1532-8708Online Volltext: dx.doi.org/ -
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cellsIn: Cellular and Molecular Life Sciences - CMLS Jg. 67 (2010) Nr. 5, S. 817 - 828
ISSN: 1420-682X; 1420-9071; 0014-4754Online Volltext: dx.doi.org/ -
VorwortIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 4, S. 1
ISSN: 2296-5262Online Volltext: dx.doi.org/ -
VorwortIn: Oncology Research and Treatment Jg. 37 (2014) S. 1
ISSN: 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
VorwortIn: Onkologie Jg. 35 (2012) Nr. Suppl. 2, S. 1
ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ (Open Access) -
VorwortIn: Onkologie Jg. 34 (2011) Nr. SUPPL. 2, S. 1
ISSN: 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Comparing 5-year body-mass-index gain of people living with HIV (PLH) with the general populationIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 23
ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Comparing 5-year body-mass-index gain of people living with HIV (PLH) with the general populationIn: Infection Jg. 49 (2021) Nr. Suppl. 1, S. 23
ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Efficacy of syphilis treatment in HIV-infected patientsIn: Infection Jg. 49 (2021) Nr. Suppl. 1, S. 40
ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Efficacy of trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia marker lesions in HIV-positive patientsIn: Infection Jg. 49 (2021) Nr. Suppl. 1, S. 24 - S25
ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ (Open Access) -
Efficacy of trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia marker lesions in HIV-positive patientsIn: Infection Jg. 49 (2021) Nr. Suppl. 1, S. 24 - S25
ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ (Open Access) -
5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO plus IPI) or NIVO aloneIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S734 - S735
ISSN: 0923-7534Online Volltext: dx.doi.org/ -
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28
ISSN: 1563-2571; 1610-0387; 0301-0481; 1610-0379Online Volltext: dx.doi.org/ -
Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUSIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S757 - S758
ISSN: 0923-7534Online Volltext: dx.doi.org/ -
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Distinct melanoma differentiation trajectories driven by MAPKi associate with activation of CD8+tumor-infiltrating lymphocytesIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV17
ISSN: 1563-2571; 1610-0387; 0301-0481; 1610-0379Online Volltext: dx.doi.org/ -
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanomaIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10034
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Effektivität von Dabrafenib plus Trametinib bei der Behandlung von Melanompatienten mit BRAFV600‐mutierten HirnmetastasenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P128
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Einfluss des BRAF‐V600 Mutationsstatus auf die Effizienz einer Immun‐Checkpoint‐Blockade : Eine Auswertung des ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV33
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Encorafenib plus Binimetinib bei Patienten mit lokal fortgeschrittenem, inoperablem oder metastasiertem BRAFV600‐mutierten Melanom : Erste Daten der multizentrischen, multinationalen, prospektiven, nicht‐interventionellen Längsschnittstudie BERINGMELANOMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P130
ISSN: 1563-2571; 1610-0387; 0301-0481; 1610-0379Online Volltext: dx.doi.org/ -
E‐Health trifft auf „Real‐World“ : App‐basierte Unterstützung in der adjuvanten Therapie von Melanompatienten im Stadium III mit Dabrafenib und Trametinib (Combi‐EU)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV45
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Immun‐Checkpoint‐Blockade beim Merkelzellkarzinom : Klinische und molekulare Biomarker‐AnalyseIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV22
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. Suppl. 3, S. A308
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma : Five-year analysis of COMBI-ADIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10001
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44
ISSN: 1563-2571; 1610-0387; 0301-0481; 1610-0379Online Volltext: dx.doi.org/ -
Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases : Real-world evidence from the German non-interventional study NICOIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. 746 - S747
ISSN: 0923-7534Online Volltext: dx.doi.org/ -
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) : Longer follow-upIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl.,
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal Jg. 41 (2020) Nr. Supplement_2, S. 3260
ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodiesIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. Suppl. 2, S. A3
ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access) -
Real World‐ Daten zur Anwendung von Nivolumab (Nivo) als Monotherapie oder in Kombination mit Ipilimumab (Nivo+Ipi) in der Behandlung des fortgeschrittenen Melanoms : Zwischenergebnisse der nicht‐interventionellen Studie NICOIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P101
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. 743 - S744
ISSN: 0923-7534Online Volltext: dx.doi.org/ -
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma : Results from the randomized part 3 of the phase III COMBI-i trialIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S1172
ISSN: 0923-7534Online Volltext: dx.doi.org/ -
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma : Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trialIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10028
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
Tumor necrosis factor alpha blockade prevents immune checkpoint inhibitor therapy-related cardiotoxicity
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal Jg. 41 (2020) Nr. Supplement_2, S. 3250
ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
Tumorzell‐intrinsiche Aktivierung des Immunrezeptors RIG‐I in Kombination mit Immun‐Checkpoint‐Blockade verbessert anti‐Tumor T‐ZellantwortenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV18
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Update zum Gesamtüberleben in der COLUMBUS‐Studie : Eine randomisierte Phase 3‐Studie mit Encorafenib (ENCO) plus Binimetinib (BINI) vs Vemurafenib (VEM) oder ENCO bei Patienten mit BRAF V600–mutiertem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P127
ISSN: 1610-0387; 1610-0379Online Volltext: dx.doi.org/ -
A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)In: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9582 - 9582
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Der Stellenwert der Schildwächterlymphknotenentnahme auf das metastasenfreie Überleben von Patienten mit Hoch- risiko-PlattenepithelkarzinomenIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 17 (2019) Nr. Suppl. 5, S. 23 - 23
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Development of therapeutic strategies by resolving the tumor ecosystemIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,
ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/ -
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanomaIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9507 - 9507
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Genomic analyses and immunotherapy in advanced melanomaIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,
ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/ -
Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI : CheckMate 067 4-year dataIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9551 - 9551
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 6015 - 6015
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, September 30 - October 3, 2018, New York, NY,In: Cancer Immunology Research: Illuminating the interplay of cancer and the immune system Jg. 7 (2019) Nr. 2, Supplement, S. A082
ISSN: 2326-6066; 2326-6074Online Volltext: dx.doi.org/ -
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma : Updated efficacy and safety from parts 1 and 2 of COMBI-iIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9531 - 9531
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9515 - 9515
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Update on overall survival in COLUMBUS : A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanomaIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 9512 - 9512
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Variants in CD5 and IRF4 impact into melanoma survivalIn: European Journal of Human Genetics Jg. 26 (2019) Nr. Suppl., S. 688 - 689
ISSN: 1018-4813Online Volltext: dx.doi.org/ -
1246PD - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: : Evidence for systemic effects in a phase II, single-arm studyIn: Annals of Oncology Jg. 29 (2018) Nr. 8, S. viii443
ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access) -
A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii464 - viii465
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii465 - viii466
ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC) : A randomized, multicenter DeCOG/ADO studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9527
ISSN: 1527-7755; 0732-183XOnline Volltext: dx.doi.org/ -
Adjuvante Therapie des Merkelzellkarzinoms mit Ipilimumab im Vergleich zur Beobachtung (ADMEC) : eine randomisierte, multizentrische ADO‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 6
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Angiosarkom im Bereich des Capillitium mit der Symptomatik eines Quincke‐Ödems
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 16 (2018) Nr. Suppl. 6, S. 34
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Application of circulating cell-free tumor DNA (ctDNA) profiles for monitoring metastatic melanoma progression under therapy
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e22 - e23
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Biomarkers of response to PD‐1 inhibition in Merkel cell carcinoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 5
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Catch me if you can! : Novel immune escape mechanisms in melanoma metastases of the brain
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e15
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 16 (2018) Nr. Suppl. 6, S. 3
ISSN: 1610-0379; 1610-0387 -
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
EUMelaReg : A European platform for outcome research on real world treatment data of patients with advanced melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii459
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28 - 29
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Evolution of cross‐resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. 6, S. 53
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
F-18-FDG PET/MR including DWI in initial N-Staging in patients with malignant melanoma : Is it a possible replacement for sentinel lymph node biopsy?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 38
ISSN: 1619-7089Online Volltext: dx.doi.org/ -
Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3036
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Gesamtüberleben (OS) in COLUMBUS: eine Phase‐III‐Studie mit Encorafenib (ENCO) plus Binimetinib (BINI) vs. Vemurafenib (VEM) oder ENCO beim BRAF‐mutierten Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 41
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Gesichtsalterungs‐Apps in Warteräumen : Eine neue Möglichkeit für die Hautkrebsprävention?
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 66 - 67
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Gesichtsalterungs‐Apps in Warteräumen von HIV‐positiven Patienten zur Tabakentwöhnung : Führt die öffentliche Selfiebearbeitung zum Aufhörversuch? – eine Interventionsstudie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 65 - 66
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Gesichtsalterungs‐Apps in der schulischen Melanomprävention: : erste Ergebnisse aus Deutschland und Brasilen – Perspektiven für großflächige Implementation
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 67
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial : An international randomized double-blind phase III trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii456
ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access) -
Impact of skin cancer screening on the incidence of advanced melanoma and melanoma mortality : A pilot project for a case-control study in the setting of the German nationwide skin cancer screening (PiKoM)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 159
ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ -
Interaction of neutrophils and melanoma in the context of MAP kinase inhibition
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e85 - e86
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Künstliche Intelligenz in der dermatologischen Diagnostik : Das Skin‐Classification‐Projekt
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
MEK‐Inhibitoren könnten das Überleben von NRAS‐mutierten Melanompatienten unter Checkpoint‐Inhibitoren verbessern : Ergebnisse einer retrospektiven, multizentrischen Analyse von 364 Patienten
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 4
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Meningeosis melanomatosa : schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
NICO ‐ eine nationale, prospektive, nicht‐interventionelle Studie (NIS) mit Nivolumab als Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom zur Erhebung von real‐world data
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 79
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Overall survival in COLUMBUS : A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanomaIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9504 - 9504
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
PAKOME‐RCT: Projektskizze für die Evaluation des Einsatzes einer evidenzbasierten Patienteninformation (EBPI) zum Melanom in der Praxis
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 60
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma : Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trialIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Phase 3 Randomized Eortc 1325‐Mg/Keynote‐054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High‐Risk Stage III Melanoma
Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, New Directions in Personalised Cancer Therapy; 1–3 August 2018; Adelaide, Australia,In: Asia-Pacific Journal of Clinical Oncology Jg. 14 (2018) Nr. Supplement 3, S. 48
ISSN: 1743-7563; 1743-7555Online Volltext: dx.doi.org/ -
Potential role of TGF-beta signaling in immune-checkpoint-therapy-induced resistance in malignant melanoma
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e63 - e64
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9519 - 9519
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Prognostic impact of baseline tumor immune infiltrate on disease-free survival (DFS) in patients with completely resected, BRAF(V600) mutation-positive (BRAF(V600+)) melanoma receiving adjuvant vemurafenib
Immunotherapy Bridge 2017 and Melanoma Bridge 2017 ; 29 November–2 December 2017. Naples, Italy,In: Journal of Translational Medicine Jg. 16 (2018) Nr. Suppl. 1, S. O20
ISSN: 1479-5876Online Volltext: dx.doi.org/ (Open Access) -
Prospektive Studie zur Evaluation der perioperativen Angst und des Speichelkortisollevels bei Melanompatienten mit Schildwächterlymphknotenexstirpationen in Tumeszenz‐ vs. Vollnarkose
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 62
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Real-world evidence in melanoma : A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 159
ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ -
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockadeIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3074 - 3074
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma : First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-iIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Unerwünschte Ereignisse von besonderem Interesse in der Phase‐3‐COLUMBUS‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 42
ISSN: 1563-2571; 0301-0481Online Volltext: dx.doi.org/ -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Mechanistic analysis of CD3-driven T cell functions reveals a CD32a polymorphism associated with melanoma emergenceIn: Experimental Dermatology Jg. 24 (2015) Nr. 3, 42nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), March 05-07, 2015, Ulm, Germany, S. E18 - E18
ISSN: 0906-6705; 1600-0625Online Volltext: dx.doi.org/ -
Senescence-like responses in irradiated melanoma cellsIn: Journal der Deutschen Dermatologischen Gesellschaft Jg. 13 (2015) Nr. Suppl.2, S. 34
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002) : Decog-trialIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. 9071
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
BRIM8 : A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419)In: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, Suppl., S. TPS9118
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Brain natriuretic peptide (BNP) as a prognostic parameter for cardiovascular events and death in HV-infected patients
ESC Congress 2014, Barcelona, Spain, 30 August – 3 September 2014,In: European Heart Journal Jg. 35 (2014) Nr. Suppl. 1, S. 231
ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinibIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, Suppl., S. 9062
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Left ventricular ejection fraction as a prognostic marker for all-cause mortality in HIV-infected patients
ESC Congress 2016, 27 - 31 August, Rome, Italy,In: European Heart Journal Jg. 35 (2014) Nr. Suppl. 1, S. 3
ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : Final update (30-month) of the pivotal ERIVANCE BCC studyIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, Suppl., S. 9013
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763)In: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. 9034
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
NEMO : A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanomaIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. TPS9102 - TPS9102
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroupsIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, Suppl., S. 9031
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Proktitiden mit N. gonorrhoeae/C. trachomatis führen zur Rekrutierung von HIV-Zielzellen aber nicht zu einer gesteigerten HIV-Sekretion
Leopoldina-Symposium und STI-Kongress, 18. und 19.–21. Juni 2014, Berlin,In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 12 (2014) Nr. 10, S. 952 - 953
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Shift of HIV-Tropism in a HIV-patient with large cell anaplastic T-cell-lymphoma undergoing allogeneic stem cell transplantation from a donor with homozygosity for the CCR5 delta32 mutation
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 38
ISSN: 2296-5262Online Volltext: dx.doi.org/ -
The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatmentIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. TPS9113
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinibIn: Journal of Clinical Oncology Jg. 32 (2014) Nr. 15, suppl., S. 9061
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Neuropilin-1 mediates infiltration of regulatory T cells into tumors favoring immune escapeIn: Eur J Immunol Jg. 190 (2013) S. P2063
ISSN: 0014-2980; 1521-4141 -
Oncogene and copy number analysis of a larger cohort of conjunctival melanomaIn: Experimental Dermatology Jg. 22 (2013) Nr. 3, S. E43
ISSN: 0906-6705; 1600-0625 -
A five-year observance of changes in the cardiovascular risk profile in 505 HIV-positive individualsIn: Journal of the International AIDS Society / Eleventh International Congress on Drug Therapy in HIV Infection; 11-15 November 2012; Glasgow, UK Jg. 15 (2012) Nr. S4, S. P211
ISSN: 1758-2652Online Volltext: dx.doi.org/ (Open Access) -
A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairsIn: Cancer Research / AACR 103rd Annual Meeting 2012 ; Mar 31‐Apr 4, 2012, Chicago Jg. 72 (2012) Nr. 8, Suppl., S. 5056
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
HIV-infection during treatment of a chronic hepatitis B virus infection : implications for PrEP?In: Journal of the International AIDS Society / Eleventh International Congress on Drug Therapy in HIV Infection; 11-15 November 2012; Glasgow, UK Jg. 15 (2012) Nr. S4, S. P234
ISSN: 1758-2652Online Volltext: dx.doi.org/ -
METRIC phase III study : Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM)In: Journal of Clinical Oncology Jg. 30 (2012) Nr. 18, Suppl., S. LBA8509
ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Cardiovascular Risk factors of Psoriasis : Results from the Heinz Nixdorf Recall Study
46. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V., 30. März bis 2. April 2011, Dresden,In: Journal der Deutschen Dermatologischen Gesellschaft Jg. 9 (2011) Nr. S1, Abstraktband anläßlich der 46. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V. in Dresden vom 30. März bis 2. April 2011, S. 147 - 148
ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/ -
Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survivalIn: Cancer Research / AACR 102nd Annual Meeting 2011 ; Apr 2‐6, 2011, Orlando Jg. 71 (2011) Nr. 8, Suppl., S. 4835
ISSN: 0008-5472; 1538-7445Online Volltext: dx.doi.org/ -
The era of checkpoint inhibition : Lessons learned from melanomaIn: Current Immunotherapeutic Strategies in Cancer / Theobald, Matthias (Hrsg.) 2020, S. 169 - 187
ISBN: 978-3-030-23764-6; 978-3-030-23765-3Online Volltext: dx.doi.org/ -
Immune checkpoint inhibitors in melanoma define a new era in immunotherapy aiming for cureIn: Melanoma Development: Molecular Biology, Genetics and Clinical Application / Bosserhoff, Anja K. (Hrsg.) 2017, S. 427 - 436
ISBN: 978-3-319-41319-8; 978-3-319-41317-4Online Volltext: dx.doi.org/ -
The common and the unusual presentation of skin metastases in cancer patientsIn: Handbook of Skin Care in Cancer Patients / Awada, Ahmad; Vereecken, Pierre (Hrsg.) 2012, S. 95 - 115
ISBN: 9781616684198 -
High-resolution 3-D imaging for precise staging in malignant melanomaNew York (2020) 37 Seiten
Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
The Janus-faced role of KDM5B heterogeneity in melanoma : Differentiation as a situational driver of both growth arrest and drug-resistance(2020) 50 Seiten
Online Volltext: dx.doi.org/ (Open Access)